Dataset Preview
The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
The dataset generation failed
Error code: DatasetGenerationError
Exception: ArrowInvalid
Message: Failed to parse string: 'Fire Technology' as a scalar of type double
Traceback: Traceback (most recent call last):
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1871, in _prepare_split_single
writer.write_table(table)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/arrow_writer.py", line 643, in write_table
pa_table = table_cast(pa_table, self._schema)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 2293, in table_cast
return cast_table_to_schema(table, schema)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 2246, in cast_table_to_schema
arrays = [
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 2247, in <listcomp>
cast_array_to_feature(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 1796, in wrapper
return pa.chunked_array([func(chunk, *args, **kwargs) for chunk in array.chunks])
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 1796, in <listcomp>
return pa.chunked_array([func(chunk, *args, **kwargs) for chunk in array.chunks])
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 2103, in cast_array_to_feature
return array_cast(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 1798, in wrapper
return func(array, *args, **kwargs)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 1950, in array_cast
return array.cast(pa_type)
File "pyarrow/array.pxi", line 996, in pyarrow.lib.Array.cast
File "/src/services/worker/.venv/lib/python3.9/site-packages/pyarrow/compute.py", line 404, in cast
return call_function("cast", [arr], options, memory_pool)
File "pyarrow/_compute.pyx", line 590, in pyarrow._compute.call_function
File "pyarrow/_compute.pyx", line 385, in pyarrow._compute.Function.call
File "pyarrow/error.pxi", line 154, in pyarrow.lib.pyarrow_internal_check_status
File "pyarrow/error.pxi", line 91, in pyarrow.lib.check_status
pyarrow.lib.ArrowInvalid: Failed to parse string: 'Fire Technology' as a scalar of type double
The above exception was the direct cause of the following exception:
Traceback (most recent call last):
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1433, in compute_config_parquet_and_info_response
parquet_operations = convert_to_parquet(builder)
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1050, in convert_to_parquet
builder.download_and_prepare(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 925, in download_and_prepare
self._download_and_prepare(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1001, in _download_and_prepare
self._prepare_split(split_generator, **prepare_split_kwargs)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1742, in _prepare_split
for job_id, done, content in self._prepare_split_single(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1898, in _prepare_split_single
raise DatasetGenerationError("An error occurred while generating the dataset") from e
datasets.exceptions.DatasetGenerationError: An error occurred while generating the datasetNeed help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.
Record Number
int64 | Reference Type
string | Author
string | Year
float64 | Title
string | Secondary Author
null | Secondary Title
string | Publisher
null | Volume
float64 | Number of Volumes
string | Number
string | Pages
string | Section
string | Tertiary Author
null | Tertiary Title
null | Edition
string | Date
string | Type of Work
null | Subsidiary Author
null | Short Title
string | Alternate Title
string | ISBN/ISSN
string | Original Publication
null | Reprint Edition
null | Reviewed Item
null | Custom 1
string | Custom 2
string | Custom 3
null | Custom 4
null | Custom 5
null | Custom 6
null | Custom 7
null | Custom 8
string | Accession Number
float64 | Call Number
null | Label
null | Keywords
string | Abstract
string | Notes
string | Research Notes
null | URL
string | Author Address
string | Figure
null | Caption
null | Access Date
null | Translated Author
null | Translated Title
null | Name of Database
string | Database Provider
string | Language
string | Publisher location
null | DOI
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Generic | Arth, A. K., V., Pachon, H., Zimmerman, S., Johnson, Q., Oakley, G. P., Jr., | 2,016 | A 2015 global update on folic acid-preventable spina bifida and anencephaly | null | Birth Defects Res A Clin Mol Teratol | null | 106 | null | 7 | 520-529 | null | null | null | 7/16/2016 | Jul | null | null | A 2015 global update on folic acid-preventable spina bifida and anencephaly | Birth defects research. Part A, Clinical and molecular teratology | 1542-0752 | null | null | null | CDC Public Health Grand Rounds | Maternal and Child Health - Global Prevention of Neural Tube Defects | null | null | null | null | null | 9:41 | 27,418,029 | null | null | anencephaly: epidemiology: flour fortification: folic acid: prevention: spina bifida | BACKGROUND: Spina bifida and anencephaly are two major neural tube defects. They contribute substantially to perinatal, neonatal, infant, and under-five mortality and life-long disability. To monitor the progress toward the total prevention of folic acid-preventable spina bifida and anencephaly (FAP SBA), we examined their global status in 2015. METHODS: Based on existing data, we modeled the proportion of FAP SBA that are prevented in the year 2015 through mandatory folic acid fortification globally. We included only those countries with mandatory fortification that added at least 1.0 ppm folic acid as a fortificant to wheat and maize flour, and had complete information on coverage. Our model assumed mandatory folic acid fortification at 200 mug/day is fully protective against FAP SBA, and reduces the rate of spina bifida and anencephaly to a minimum of 0.5 per 1000 births. RESULTS: Our estimates show that, in 2015, 13.2% (35,500 of approximately 268,700 global cases) of FAP SBA were prevented in 58 countries through mandatory folic acid fortification of wheat and maize flour. Most countries in Europe, Africa, and Asia were not implementing mandatory fortification with folic acid. CONCLUSION: Knowledge that folic acid prevents spina bifida and anencephaly has existed for 25 years, yet only a small fraction of FAP SBA is being prevented worldwide. Several countries still have 5- to 20-fold epidemics of FAP SBA. Implementation of mandatory fortification with folic acid offers governments a proven and rapid way to prevent FAP SBA-associated disability and mortality, and to help achieve health-related Sustainable Development Goals. Birth Defects Research (Part A) 106:520-529, 2016. (c) 2016 Wiley Periodicals, Inc. | 1542-0760: Arth, Annelise: Kancherla, Vijaya: Pachon, Helena: Zimmerman, Sarah: Johnson, Quentin: Oakley, Godfrey P Jr: Journal Article: United States: Birth Defects Res A Clin Mol Teratol. 2016 Jul;106(7):520-9. doi: 10.1002/bdra.23529. | null | http://www.ncbi.nlm.nih.gov/pubmed/27418029 | Center for Spina Bifida Prevention, Department of Epidemiology, Rollins School of Public Health of Emory University, Atlanta, Georgia.: Food Fortification Initiative, Atlanta, Georgia.: Hubert Department of Global Health, Rollins School of Public Health of Emory University, Atlanta, Georgia. | null | null | null | null | null | null | NLM | eng | null | 10.1002/bdra.23529 |
2 | Generic | Liu, G. Z., G., Dhana, K., Hu, Y., Blount, B. C., Morel-Espinosa, M., Sun, Q., | 2,017 | Exposure to perchlorate, nitrate and thiocyanate, and prevalence of diabetes mellitus | null | Int J Epidemiol | null | null | null | null | null | null | null | null | 10/13/2017 | 9-Nov | null | null | Exposure to perchlorate, nitrate and thiocyanate, and prevalence of diabetes mellitus | International journal of epidemiology | 0300-5771 | null | null | null | CDC Authored Publications | Chronic Diseases and Conditions | null | null | null | null | null | 9:42 | 29,025,080 | null | null | Perchlorate: diabetes: epidemiology: insulin resistance: nitrate: thiocyanate | Background: It is known that perchlorate, nitrate and thiocyanate have the property of inhibiting sodium iodide symporter. Animal studies have suggested that these compounds, especially perchlorate, might also interfere with insulin secretion. However, the association between their exposure and diabetes risk is largely unknown in humans. Methods: Among 11 443 participants (mean age 42.3 years) from the National Health and Nutritional Examination Survey 2001-14, urinary perchlorate, nitrate and thiocyanate were measured by using ion chromatography coupled with electrospray tandem mass spectrometry. Diabetes was defined as self-reported doctor diagnosis, use of oral hypoglycaemic medication or insulin, fasting plasma glucose >/= 126 mg/dl or glycated haemoglobin A1c (HbA1c) >/= 6.5%. Results: The median (interquartile range) levels of urinary perchlorate, nitrate and thiocyanate were 3.32 (1.84, 5.70) mug/l, 46.4 (27.9, 72.0) mg/l and 1.23 (0.59, 2.78) mg/l, respectively. Higher levels of urinary perchlorate were associated with elevated levels of fasting glucose, HbA1c, insulin and homeostatic model assessment of insulin resistance (all P trend < 0.001). After multivariate adjustment including urinary creatinine, smoking status and body mass index (BMI), higher urinary perchlorate, but not nitrate or thiocyanate, was associated with an increased prevalence of diabetes mellitus. Comparing extreme quintiles, the odds ratio (95% confidence interval) of diabetes was 1.53 (1.21, 1.93; P trend < 0.001) for perchlorate, 1.01 (0.77, 1.32; P trend = 0.44) for nitrate and 0.98 (0.73, 1.31; P trend = 0.64) for thiocyanate. When urinary perchlorate, nitrate and thiocyanate were further mutually adjusted, the results did not materially change. Similar results were observed when analyses were stratified by smoking status, as well as by age, gender, kidney function and BMI. Conclusions: Higher urinary perchlorate levels are associated with an increased prevalence of diabetes mellitus, independent of traditional risk factors. Future prospective studies are needed to confirm these findings. | 1464-3685: Liu, Gang: Zong, Geng: Dhana, Klodian: Hu, Yang: Blount, Benjamin C: Morel-Espinosa, Maria: Sun, Qi: Journal Article: England: Int J Epidemiol. 2017 Sep 11. doi: 10.1093/ije/dyx188. | null | https://www.ncbi.nlm.nih.gov/pubmed/29025080 | Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.: Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, GA, USA.: Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. | null | null | null | null | null | null | NLM | eng | null | 10.1093/ije/dyx188 |
9,667 | Generic | Koneru, A. S., S.;Roberts, H.;Sirotkin, B.;Fenlon, N.;Murphy, T. V.;Nelson, N. P. | 2,019 | Estimating annual births to hepatitis B surface antigen-positive women in the United States by using data on maternal country of birth | null | Public Health Rep | null | null | null | null | 3.34E+13 | null | null | null | 4/5/2019 | 4-Mar | null | null | Estimating annual births to hepatitis B surface antigen-positive women in the United States by using data on maternal country of birth | Public health reports (Washington, D.C. : 1974) | 0033-3549 | null | null | null | CDC Authored Publications | Communicable Diseases | null | null | null | null | null | 11:15 | 30,943,844 | null | null | hepatitis B:infants:perinatal | OBJECTIVE:: A national estimate of births to hepatitis B surface antigen (HBsAg)-positive women can help public health programs plan surveillance, educational, and outreach activities to improve identification and management of at-risk women and infants. Stratifying mothers by country of birth allows for the application of region-specific HBsAg prevalence estimates, which can more precisely estimate the number of at-risk infants. The objective of our study was to estimate the number of births to HBsAg-positive women in the United States with more granularity than previous models. METHODS:: We developed a model that incorporated maternal country of birth (MCOB) and updated HBsAg prevalence estimates. We assessed birth certificate data by MCOB, and we stratified US-born mothers by race/ethnicity, US territory-born mothers by territory, and non-US-born mothers by region. We multiplied and summed data in each subcategory by using HBsAg prevalence estimates calculated from the 2009-2014 National Health and Nutrition Examination Surveys or Perinatal Hepatitis B Prevention Program. We compared the findings of our MCOB model with a race/ethnicity model. RESULTS:: In 2015, an estimated 20 678 infants were born to HBsAg-positive women in the United States, representing 0.5% of all births. Births to US-born and non-US-born women comprised 77.2% and 21.5% of all births, respectively, and 40.1% and 57.9% of estimated births to HBsAg-positive women, respectively. The estimated contribution of births to HBsAg-positive women varied by MCOB region, from 4 (0.03%) infants born to women from Australia/Oceania to 5795 (28.0%) infants born to women from East Asia. Our MCOB model estimated 5666 fewer births to HBsAg-positive women than did the race/ethnicity model. CONCLUSIONS:: As global vaccine programs reduce HBsAg prevalence, the MCOB model can incorporate evolving HBsAg prevalence estimates for women from various regions of the world. | 1468-2877:Koneru, Alaya:Schillie, Sarah:Roberts, Henry:Sirotkin, Barry:Fenlon, Nancy:Murphy, Trudy V:Nelson, Noele P:Journal Article:United States:Public Health Rep. 2019 Apr 3:33354919836958. doi: 10.1177/0033354919836958. | null | https://www.ncbi.nlm.nih.gov/pubmed/30943844 | 1 Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.:2 Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. | null | null | null | null | null | null | NLM | eng | null | 10.1177/0033354919836958 |
3 | Generic | Crepaz, N. T., T., Marks, G., Hall, H. I., | 2,017 | Changes in viral suppression status among HIV patients receiving care: United States, 2014 | null | Aids | null | null | null | null | null | null | null | null | 10/14/2017 | 10-Dec | null | null | Changes in viral suppression status among HIV patients receiving care: United States, 2014 | AIDS (London, England) | 0269-9370 | null | null | null | Top Articles of the Week | Communicable Diseases | null | null | null | null | null | 9:43 | 29,028,661 | null | null | null | OBJECTIVE: To examine changes in viral suppression status among HIV patients receiving care in 2014 and the extent of viral suppression among persons with infrequent care visits. METHODS: Using data reported to the National HIV Surveillance System from 33 jurisdictions with complete reporting of CD4 and viral load tests, we created four viral suppression status groups based on their first and last viral loads in 2014: both suppressed, first unsuppressed and last suppressed (improved), first suppressed and last unsuppressed (worsened), and both unsuppressed. We also calculated the number and percentage of persons whose sole viral load in 2014 was suppressed and had a suppressed viral load at their last test in 2013. RESULTS: Among 339515 persons with at least two viral load tests in 2014, 72.6% had all viral loads suppressed (durably suppressed); 75.5% had the first and last tests suppressed, 10.5% improved, 4.2% worsened, and 9.9% had both unsuppressed. Among 92309 persons who had only one viral load test in 2014, 69960 (75.8%) were suppressed and, of those, 53834 (76.9%) also had a suppressed viral load at their last test in 2013. CONCLUSIONS: National surveillance data show that the majority of patients in HIV care during 2014 were durably suppressed. More showed improved compared to worsened viral suppression status. Some patients who have less frequent care visits have sustained viral suppression. Yet one in ten who were in regular care did not have a suppressed viral load in 2014, indicating missed opportunities for clinical interventions to help patients achieve and sustain viral suppression. | 1473-5571:Crepaz, Nicole:Tang, Tian:Marks, Gary:Hall, H Irene:Journal Article:England:AIDS. 2017 Oct 12. doi: 10.1097/QAD.0000000000001660. | null | http://www.ncbi.nlm.nih.gov/pubmed/29028661 | aDivision of HIV/AIDS Prevention, the U.S. Centers for Disease Control and Prevention, Atlanta, Georgia bICF International, Atlanta, Georgia. | null | null | null | null | null | null | NLM | eng | null | 10.1097/qad.0000000000001660 |
4 | Generic | Auld, A. F. V., Pelletier, Robin, E. G., Shiraishi, R. W., Dee, J., Antoine, M., Desir, Y., Desforges, G., Delcher, C., Duval, N., Joseph, N., Francois, K., Griswold, M., Domercant, J. W., Patrice Joseph, Y. A., Van Onacker, J. D., Deyde, V., Lowrance, D. W., And The Groupe d'Analyses, Salvh, | 2,017 | Retention throughout the HIV care and treatment cascade: from diagnosis to antiretroviral treatment of adults and children living with HIV-Haiti, 1985-2015 | null | Am J Trop Med Hyg | null | null | 97 | null | 4_Suppl | 57-70 | null | null | 10/25/2017 | Oct | null | null | Retention throughout the HIV care and treatment cascade: from diagnosis to antiretroviral treatment of adults and children living with HIV-Haiti, 1985-2015 | The American journal of tropical medicine and hygiene | 0002-9637 | null | null | null | Top Articles of the Week | Communicable Diseases | null | null | null | null | null | 9:44 | 29,064,357 | null | null | null | Monitoring retention of people living with HIV (PLHIV) in the HIV care and treatment cascade is essential to guide program strategy and evaluate progress toward globally-endorsed 90-90-90 targets (i.e., 90% of PLHIV diagnosed, 81% on sustained antiretroviral therapy (ART), and 73% virally suppressed). We describe national retention from diagnosis throughout the cascade for patients receiving HIV services in Haiti during 1985-2015, with a focus on those receiving HIV services during 2008-2015. Among the 266,256 newly diagnosed PLHIV during 1985-2015, 49% were linked-to-care, 30% started ART, and 18% were retained on ART by the time of database closure. Similarly, among the 192,187 newly diagnosed HIV-positive patients during 2008-2015, 50% were linked to care, 31% started ART, and 19% were retained on ART by the time of database closure. Most patients (90-92%) at all cascade steps were adults (>/= 15 years old), among whom the majority (60-61%) were female. During 2008-2015, outcomes varied significantly across 42 administrative districts (arrondissements) of residence; cumulative linkage-to-care ranged from 23% to 69%, cumulative ART initiation among care enrollees ranged from 2% to 80%, and cumulative ART retention among ART enrollees ranged from 30% to 88%. Compared with adults, children had lower cumulative incidence of ART initiation among care enrollees (64% versus 47%) and lower cumulative retention among ART enrollees (64% versus 50%). Cumulative linkage-to-care was low and should be prioritized for improvement. Variations in outcomes by arrondissement and between adults and children require further investigation and programmatic response. | 1476-1645:Auld, Andrew F:Valerie Pelletier:Robin, Ermane G:Shiraishi, Ray W:Dee, Jacob:Antoine, Mayer:Desir, Yrvel:Desforges, Gracia:Delcher, Chris:Duval, Nirva:Joseph, Nadjy:Francois, Kesner:Griswold, Mark:Domercant, Jean Wysler:Patrice Joseph, Yves Anthony:Van Onacker, Joelle Deas:Deyde, Varough:Lowrance, David W:And The Groupe d'Analyses Salvh:Journal Article:United States:Am J Trop Med Hyg. 2017 Oct;97(4_Suppl):57-70. doi: 10.4269/ajtmh.17-0116. | null | http://www.ncbi.nlm.nih.gov/pubmed/29064357/?otool=cdciclib | Division of Global HIV & Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.:Division of Global HIV & Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Port au Prince, Haiti.:Programme National de Lutte contre le VIH/SIDA (National AIDS Program), Ministere de la Sante Publique et de la Population (Ministry of Health), Port au Prince, Haiti.:National Alliance of State and Territorial AIDS Directors (NASTAD), Port-au-Prince, Haiti.:Department of Health Outcomes and Policy, University of Florida, Gainesville, Florida.:National Alliance of State and Territorial AIDS Directors (NASTAD), Washington, District of Columbia. | null | null | null | null | null | PubMed | NLM | eng | null | 10.4269/ajtmh.17-0116 |
5 | Generic | Goldenholz, D. M. S., A., Cook, M., Moss, R., Theodore, W. H., | 2,017 | A multi-dataset time-reversal approach to clinical trial placebo response and the relationship to natural variability in epilepsy | null | Seizure | null | 53 | null | null | 31-36 | null | null | null | 11/6/2017 | 23-10 | null | null | A multi-dataset time-reversal approach to clinical trial placebo response and the relationship to natural variability in epilepsy | Seizure | 1059-1311 | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 9:46 | 29,102,709 | null | null | Big data:Placebo:Placebo effect:Randomized clinical trial:Seizure diary:Simulation:Statistics | PURPOSE: Clinical epilepsy drug trials have been measuring increasingly high placebo response rates, up to 40%. This study was designed to examine the relationship between the natural variability in epilepsy, and the placebo response seen in trials. We tested the hypothesis that 'reversing' trial direction, with the baseline period as the treatment observation phase, would reveal effects of natural variability. METHOD: Clinical trial simulations were run with time running forward and in reverse. Data sources were: SeizureTracker.com (patient reported diaries), a randomized sham-controlled TMS trial, and chronically implanted intracranial EEG electrodes. Outcomes were 50%-responder rates (RR50) and median percentage change (MPC). RESULTS: The RR50 results showed evidence that temporal reversal does not prevent large responder rates across datasets. The MPC results negative in the TMS dataset, and positive in the other two. CONCLUSIONS: Typical RR50s of clinical trials can be reproduced using the natural variability of epilepsy as a substrate across multiple datasets. Therefore, the placebo response in epilepsy clinical trials may be attributable almost entirely to this variability, rather than the "placebo effect". | 1532-2688:Goldenholz, Daniel M:Strashny, Alex:Cook, Mark:Moss, Robert:Theodore, William H:Journal Article:England:Seizure. 2017 Oct 23;53:31-36. doi: 10.1016/j.seizure.2017.10.016. | null | http://www.ncbi.nlm.nih.gov/pubmed/29102709 | National Institutes of Health, NINDS, United States; Beth Israel Deaconess Medical Center, Department of Neurology, United States. Electronic address: [email protected].:Centers for Disease Control, United States. Electronic address: [email protected].:University of Melbourne, Department of Neurology, Australia. Electronic address: [email protected].:SeizureTracker.com, United States. Electronic address: [email protected].:National Institutes of Health, NINDS, United States. Electronic address: [email protected]. | null | null | null | null | null | null | NLM | eng | null | 10.1016/j.seizure.2017.10.016 |
9,668 | Journal Article | Bosse, D. A.;Phillips, R.A.;Harrison, J. S. | 2,009 | Stakeholders, reciprocity, and firm performance | null | Strategic Management Journal | null | 30 | null | 4 | 447-456 | null | null | null | null | null | null | null | Stakeholders, reciprocity, and firm performance | null | 0143-2095 | null | null | null | Key Scientific Articles in Featured Topic Areas: Community Health and Economic Prosperity: Engaging Businesses as Stewards and Stakeholders-A Report of the Surgeon General | Community Health and Economic Prosperity: Business | null | null | null | null | null | 13:04 | null | null | null | null | Abstract The assumption that economic actors behave in a boundedly self-interested manner promises fruitful new insights for strategic management. A growing literature spanning multiple disciplines indicates most actors' selfish utility maximizing behaviors are bounded by norms of fairness. Rather than being purely self-interested, people behave reciprocally by rewarding others whose actions they deem fair and willingly incurring costs to punish those they deem unfair. Economists show that employers who are perceived as distributionally fair by their employees generate comparatively more value due to the positively reciprocal behavior of those employees. The organizational justice literature distinguishes two additional types of fairness assessed by employees. Drawing from both these bodies of work, we employ stakeholder theory to propose how perceptions of fairness result in reciprocity (1) extending to all stakeholders of the firm and (2) affecting firm performance. | null | null | https://onlinelibrary.wiley.com/doi/abs/10.1002/smj.743 | null | null | null | null | null | null | null | null | null | null | 10.1002/smj.743 |
6 | Generic | Hall, H. I. S., R., Szwarcwald, C. L., Green, T., | 2,015 | *Brief report: Time from infection with the human immunodeficiency virus to diagnosis, United States | null | J Acquir Immune Defic Syndr | null | null | 69 | null | 2 | 248-251 | null | null | 2/26/2015 | 6-Jan | null | null | *Brief report: Time from infection with the human immunodeficiency virus to diagnosis, United States | Journal of acquired immune deficiency syndromes (1999) | 1525-4135 | null | null | null | CDC Vital Signs | Communicable Diseases | null | null | null | null | null | 9:47 | 25,714,245 | null | null | Adolescent:Adult:Aged:Diagnostic Tests, Routine/methods/utilization:Female:HIV/*isolation & purification:HIV Infections/*diagnosis/*transmission:Humans:Male:Middle Aged:Time Factors:United States:Young Adult | HIV testing efforts increased in recent years to reduce the percentage of persons with HIV unaware of their infection and to detect HIV early. An analysis of CD4 data from national HIV surveillance indicates that diagnosis delays decreased during 2003-2011; on average, persons diagnosed in 2011 had been infected 5.6 years before their diagnosis compared with 7.0 years among those diagnosed in 2003. Diagnosis delays were longer among females, blacks, Hispanics/Latinos, and older persons, but shorter among men who have sex with men, compared with their counterparts. Continued efforts to implement routine testing can help reduce diagnosis delays. | 1944-7884:Hall, H Irene:Song, Ruiguang:Szwarcwald, Celia Landmann:Green, Timothy:Journal Article:Research Support, U.S. Gov't, Non-P.H.S.:United States:J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):248-51. doi: 10.1097/QAI.0000000000000589. | null | http://www.ncbi.nlm.nih.gov/pubmed/25714245 | *Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA; and daggerInstitute of Communication and Information Science and Technology in Health, Oswaldo Cruz Foundation, Ministry of Health, Rio de Janeiro, Brazil. | null | null | null | null | null | null | NLM | eng | null | 10.1097/qai.0000000000000589 |
7 | Generic | Armstead, T. L. W., N., Doreson, A., | 2,018 | Indicators for evaluating community- and societal-level risk and protective factors for violence prevention: Findings from a review of the literature | null | J Public Health Manag Pract | null | 24 | null | null | S42-s50 | null | null | null | 12/1/2017 | Jan/Feb | null | null | Indicators for evaluating community- and societal-level risk and protective factors for violence prevention: Findings from a review of the literature | Journal of public health management and practice : JPHMP | 1078-4659 | null | null | null | Top Ten Articles of the Week | Injury and Violence | null | null | null | null | null | 9:49 | 29,189,503 | null | null | null | Programs geared toward preventing violence before it occurs at the community and societal levels of the social ecology are particularly challenging to evaluate. These programs are often focused on impacting the antecedents (or risk and protective factors) to violence, making it difficult to determine program success when solely relying on measures of violence reduction. The goal of this literature review is to identify indicators to measure risk and protective factors for violence that are accessible and measured at the community level. Indicators of community- and societal-level risk and protective factors from 116 articles are identified. These indicators strengthen violence prevention researchers' and practitioners' ability to detect proximal effects of violence prevention programs, practices, and policies, and provide timely feedback on the impact of their work. Thus, opportunities exist for violence prevention researchers to further study the associations between various indicators and different violent outcomes and to inform practitioner, evaluator, and funder developed logic models that include indicators of relevant risk and protective factors for crosscutting violence prevention measures and outcomes. | 1550-5022:Armstead, Theresa L:Wilkins, Natalie:Doreson, Amanda:Journal Article:United States:J Public Health Manag Pract. 2018 Jan/Feb;24 Suppl 1 Supplement, Injury and Violence Prevention:S42-S50. doi: 10.1097/PHH.0000000000000681. | null | https://www.ncbi.nlm.nih.gov/pubmed/29189503 | Division of Violence Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia (Dr Armstead and Ms Doreson); and Division of Analysis, Research, and Practice Integration, Centers for Disease Control and Prevention, Atlanta, Georgia (Dr Wilkins). | null | null | null | null | null | Top Ten Articles of the Week | NLM | eng | null | 10.1097/phh.0000000000000681 |
8 | Generic | Agarwal, S. R., J. K., Isom, S., Lawrence, J. M., Klingensmith, G., Pihoker, C., Corathers, S., Saydah, S., D'Agostino, R. B., Jr., Dabelea, D., | 2,018 | Transfer from paediatric to adult care for young adults with type 2 diabetes: the SEARCH for Diabetes in Youth Study | null | Diabet Med | null | null | null | null | null | null | null | null | 1/30/2018 | 27-01 | null | null | Transfer from paediatric to adult care for young adults with type 2 diabetes: the SEARCH for Diabetes in Youth Study | Diabetic medicine : a journal of the British Diabetic Association | 0742-3071 | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 10:05 | 29,377,258 | null | null | null | AIM: To describe factors associated with transfer from paediatric to adult care and poor glycaemic control among young adults with Type 2 diabetes, using the SEARCH for Diabetes in Youth study. METHODS: Young adults with Type 2 diabetes were included if they had a baseline SEARCH visit while in paediatric care at < 18 years and >/= 1 follow-up SEARCH visit at 18-25 years. At each visit, HbA1c , BMI, self-reported demographic and healthcare provider data were collected. Associations of demographic factors with transfer of care and poor glycaemic control (HbA1c >/= 75 mmol/mol; 9.0%) were explored with multivariable logistic regression. RESULTS: Some 182 young adults with Type 2 diabetes (36% male, 75% minority, 87% with obesity) were included. Most (n = 102, 56%) reported transfer to adult care at follow-up; a substantial proportion (n = 28, 15%) reported no care and 29% did not transfer. Duration of diabetes [odds ratio (OR) 1.4, 95% confidence interval (95% CI) 1.1, 1.8] and age at diagnosis (OR 1.8, 95% CI 1.4, 2.4) predicted leaving paediatric care. Transfer to adult or no care was associated with a higher likelihood of poor glycaemic control at follow-up (adult: OR 4.5, 95% CI 1.8, 11.2; none: OR 4.6, 95% CI 1.4, 14.6), independent of sex, age, race/ethnicity or baseline HbA1c level. CONCLUSIONS: Young adults with Type 2 diabetes exhibit worsening glycaemic control and loss to follow-up during the transfer from paediatric to adult care. Our study highlights the need for development of tailored clinical programmes and healthcare system policies to support the growing population of young adults with youth-onset Type 2 diabetes. This article is protected by copyright. All rights reserved. | 1464-5491:Agarwal, S:Raymond, J K:Isom, S:Lawrence, J M:Klingensmith, G:Pihoker, C:Corathers, S:Saydah, S:D'Agostino, R B Jr:Dabelea, D:Journal Article:England:Diabet Med. 2018 Jan 27. doi: 10.1111/dme.13589. | null | https://www.ncbi.nlm.nih.gov/pubmed/29377258 | Division of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania.:Perelman School of Medicine, Philadelphia.:Pediatric Endocrinology, Children's Hospital of Los Angeles, Los Angelos.:Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem.:Department of Research, Evaluation, Kaiser Permanente Southern California, Pasadena.:Barbara Davis Center for Diabetes, University of Colorado, Children's Hospital Colorado, Denver.:Department of Pediatrics, University of Washington, Seattle.:Division of Endocrinology Department of Internal Medicine, University of Cincinnati Medical Center.:Division of Endocrinology Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati.:Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta.:Pediatrics and Epidemiology, University of Colorado, Denver, CO, USA. | null | null | null | null | null | null | NLM | eng | null | 10.1111/dme.13589 |
9,669 | Generic | Green, R. F. D., O., Crider, K. S., Olney, R. S., Archer, N., Olshan, A. F., Shapira, S. K., | 2,010 | Association of paternal age and risk for major congenital anomalies from the National Birth Defects Prevention Study, 1997 to 2004 | null | Ann Epidemiol | null | null | null | null | null | null | null | null | 1/9/2010 | 1-May | null | null | Association of paternal age and risk for major congenital anomalies from the National Birth Defects Prevention Study, 1997 to 2004 | null | 1873-2585 (Electronic): 1873-2585 (Linking) | null | null | null | CDC Authored Publications | Maternal and Child Health | null | null | null | null | null | 2:03 | 20,056,435 | null | null | null | PURPOSE: The objective of this study was to examine the associations between paternal age and birth defects of unknown etiologies while carefully controlling for maternal age. METHODS: By using 1997 to 2004 data from the National Birth Defects Prevention Study, we fit logistic regression models with paternal and maternal age as continuous variables while adjusting for demographic and other factors. RESULTS: Elevated odds ratios (ORs) for each year increase in paternal age were found for cleft palate (OR. 1.02, 95% confidence interval [95% CI], 1.00-1.04), diaphragmatic hernia (OR, 1.04; 95% CI, 1.02-1.06), right ventricular outflow tract obstruction (OR, 1.03; 95% CI, 1.01-1.04), and pulmonary valve stenosis (OR, 1.02, 95% CI, 1.01-1.04). At younger paternal ages, each year increase in paternal age correlated with increased odds of having offspring with encephalocele, cataract, esophageal atresia, anomalous pulmonary venous return, and coarctation of the aorta, but these increased odds were not observed at older paternal ages. The effect of paternal age was modified by maternal age for gastroschisis, omphalocele, spina bifida, all orofacial clefts, and septal heart defects. CONCLUSIONS: Our findings suggest that paternal age may be a risk factor for some multifactorial birth defects. | The National Birth Defects Prevention Study: Annals of epidemiology: Ann Epidemiol. 2010 Jan 5. | null | http://elib.cdc.gov:2073/science?_ob=ArticleURL&_udi=B6T44-4Y3KV4S-1&_user=856389&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000046148&_version=1&_urlVersion=0&_userid=856389&md5=eef4a58ae21a9f177cad212bf00f0219 | National Center on Birth Defects and Developmental Disabilities; Centers for Disease Control and Prevention; Atlanta, GA (R.F.G., O.D., K.S.C., R.S.O., S.K.S.); Texas Department of State Health Services; Austin, TX (N.A.); and Department of Epidemiology; University of North Carolina; Chapel Hill, NC (A.F.O.). | null | null | null | null | null | null | Nlm | Eng | null | 10.1016/j.annepidem.2009.10.009 |
9 | Generic | Ko, J. Y. W., S., Barfield, W. D., Patrick, S. W., Broussard, C. S., Yonkers, K. A., Naimon, R., Iskander, J., | 2,017 | CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome | null | MMWR Morb Mortal Wkly Rep | null | 66 | null | 9 | 242-245 | null | null | null | 3/10/2017 | 3-Oct | null | null | CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome | MMWR. Morbidity and mortality weekly report | 0149-2195 | null | null | null | CDC Public Health Grand Rounds | CDC Grand Rounds Summary | null | null | null | null | null | 10:26 | 28,278,146 | null | null | Centers for Disease Control and Prevention (U.S.):Cost of Illness:Female:Health Knowledge, Attitudes, Practice:Humans:Infant, Newborn:Legislation as Topic:Neonatal Abstinence Syndrome/epidemiology/*prevention & control:Opioid-Related Disorders/epidemiology/prevention & control:Pregnancy:Prenatal Exposure Delayed Effects:*Public Health Practice:United States/epidemiology | Neonatal abstinence syndrome (NAS) is a drug withdrawal syndrome that most commonly occurs in infants after in utero exposure to opioids, although other substances have also been associated with the syndrome (1). NAS usually appears within 48-72 hours of birth with a constellation of clinical signs, including central nervous system irritability (e.g., tremors), gastrointestinal dysfunction (e.g., feeding difficulties), and temperature instability (1) (Box 1). Opioid exposure during pregnancy might result from clinician-approved use of prescription opioids for pain relief; misuse or abuse of prescription opioids; illicit use (e.g., heroin); or medication-assisted treatment (MAT) of opioid use disorder (2) (Box 2). | 1545-861x:Ko, Jean Y:Wolicki, Sara:Barfield, Wanda D:Patrick, Stephen W:Broussard, Cheryl S:Yonkers, Kimberly A:Naimon, Rebecca:Iskander, John:Journal Article:United States:MMWR Morb Mortal Wkly Rep. 2017 Mar 10;66(9):242-245. doi: 10.15585/mmwr.mm6609a2. | null | https://www.ncbi.nlm.nih.gov/pubmed/28278146 | null | null | null | null | null | null | null | NLM | eng | null | 10.15585/mmwr.mm6609a2 |
10 | Generic | Badawy, S. M. P., A. B., Rodeghier, M. J., Liem, R. I., | 2,018 | Exercise capacity and clinical outcomes in adults followed in the Cooperative Study for Sickle Cell Disease (CSSCD) | null | Eur J Haematol | null | null | null | null | null | null | null | null | 7/13/2018 | 7-Dec | null | null | Exercise capacity and clinical outcomes in adults followed in the Cooperative Study for Sickle Cell Disease (CSSCD) | European journal of haematology | 0902-4441 | null | null | null | CDC Authored Publications | Chronic Diseases and Conditions | null | null | null | null | null | 10:27 | 29,999,202 | null | null | Sickle cell disease:acute chest syndrome:exercise capacity:fitness:mortality:pain | OBJECTIVES: To determine factors associated with exercise capacity in adults with sickle cell disease (SCD) and its relationship to hospitalizations and mortality. METHODS: A total of 223 participants in the Cooperative Study of Sickle Cell Disease (CSSCD) (64% female, 70% hemoglobin SS/Sbeta(0) thalassemia, mean age 43.3 +/- 7.5 years) underwent maximal exercise testing using a treadmill protocol with a mean duration of 11.6 +/- 5.2 minutes. RESULTS: Female sex (beta = -3.34, 95% CI [-1.80, -4.88], p < 0.001), older age (beta = -0.14, 95% CI [-0.24, -0.04], p = 0.005), higher body mass index (beta = -0.23, 95% CI [-0.37, -0.10]; p = 0.001) and lower hemoglobin (beta = 0.56, 95% CI [0.08, 1.04], p = 0.02) were independently associated with lower fitness, while there was a trend with abnormal pulmonary function testing (beta = -1.42, 95% CI [-2.92, 0.07]; p = 0.06). Lower percent predicted forced expiratory volume in 1 second (FEV1 ) was independently associated with lower fitness (beta = 0.08, 95% CI [0.03, 0.13], p = 0.001). Genotype and hospitalization rates for pain and acute chest syndrome (ACS) prior to testing were not associated with exercise capacity. Baseline exercise capacity predicted neither future pain or ACS nor survival in our cohort. Adults with SCD tolerated maximal exercise testing. CONCLUSIONS: Prospective studies are needed to further evaluate the impact of regular exercise and improved fitness on clinical outcomes and mortality in SCD. This article is protected by copyright. All rights reserved. | 1600-0609:Badawy, Sherif M:ORCID: http://orcid.org/0000-0002-4739-265X:Payne, Amanda B:Rodeghier, Mark J:Liem, Robert I:Journal Article:England:Eur J Haematol. 2018 Jul 12. doi: 10.1111/ejh.13140. | null | https://www.ncbi.nlm.nih.gov/pubmed/29999202 | Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.:Department of Pediatrics, Northwestern University Feinberg School Medicine, Chicago, IL.:Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA.:Rodeghier Consultants, Chicago, IL, USA. | null | null | null | null | null | null | NLM | eng | null | 10.1111/ejh.13140 |
11 | Generic | Ballesteros, V. C., O., Iniguez, C., Fletcher, T., Ballester, F., Lopez-Espinosa, M. J., | 2,017 | Exposure to perfluoroalkyl substances and thyroid function in pregnant women and children: A systematic review of epidemiologic studies | null | Environ Int | null | 99 | null | null | 15-28 | null | null | null | 11/26/2016 | Feb | null | null | Exposure to perfluoroalkyl substances and thyroid function in pregnant women and children: A systematic review of epidemiologic studies | Environment international | 0160-4120 | null | null | null | Key Scientific Articles in Featured Topic Areas | PFAS - Animal model and toxicology studies | null | null | null | null | null | 10:28 | 27,884,404 | null | null | Adolescent:Alkanesulfonic Acids/toxicity:Caprylates/*toxicity:Child:*Environmental Exposure:Environmental Pollutants/*toxicity:Female:Fluorocarbons/*toxicity:Humans:Male:Pregnancy:Thyroid Gland/*drug effects:*Perfluorohexane sulfonate (PFHxS):*Perfluorononanoic acid (PFNA):*Perfluorooctane sulfonate (PFOS):*Perfluorooctanoic acid (PFOA):*Prenatal and infant exposure:*Thyroid | INTRODUCTION: Thyroid hormones (THs) are especially important for brain maturation and development during the fetal period and childhood. Several epidemiological studies have assessed the possible association between exposure to perfluoroalkyl substances (PFAS) and thyroid outcomes during the early stages of life. We aimed to review this evidence. METHODS: We conducted a systematic review in compliance with the PRISMA Statement (search conducted in PubMed and Embase, as well as in the citations of the selected articles). We chose studies if they dealt with thyroid-stimulating hormone (TSH), triiodothyronine (T3), thyroxin (T4), or thyroid dysfunctions, and perfluorohexane sulfonate (PFHxS), perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS) or perfluorononanoic acid (PFNA) measured in the blood of pregnant women and/or children up to 19years old. RESULTS: We included in this review three cross-sectional, one case-control, and six cohort studies (publication: 2011-2015), focusing on prenatal life (n=7), childhood (n=2) or both periods (n=1). We observed a high degree of heterogeneity across studies in terms of sampling time (different gestational weeks, at birth, or childhood), outcomes, adjustment for potential confounders, and statistical approach. We found some evidence of a positive association between PFHxS and PFOS exposure and TSH levels measured in maternal blood, and PFNA and TSH levels measured in the blood of boys aged >/=11years. CONCLUSION: Although there is a small number of studies with comparable data, we found some consistency of a positive association between maternal or teenage male exposure to some PFAS and TSH levels based on the current literature. However, further studies are required to confirm these possible relationships. | 1873-6750:Ballesteros, Virginia:Costa, Olga:Iniguez, Carmen:Fletcher, Tony:Ballester, Ferran:Lopez-Espinosa, Maria-Jose:Journal Article:Review:Research Support, Non-U.S. Gov't:Netherlands:Environ Int. 2017 Feb;99:15-28. doi: 10.1016/j.envint.2016.10.015. Epub 2016 Nov 22. | null | https://www.ncbi.nlm.nih.gov/pubmed/27884404 | Andalusian Health and Environment Observatory (OSMAN), Andalusian School of Public Health, Campus Universitario de Cartuja, Cuesta del Observatorio, 4, 18011 Granada, Spain; Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de Valencia, Avenida de Catalunya 21, 46020 Valencia, Spain.:Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de Valencia, Avenida de Catalunya 21, 46020 Valencia, Spain.:Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de Valencia, Avenida de Catalunya 21, 46020 Valencia, Spain; Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Calle Monforte de Lemos 3-5, Madrid 28029, Spain.:London School of Hygiene & Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, United Kingdom.:Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de Valencia, Avenida de Catalunya 21, 46020 Valencia, Spain; Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Calle Monforte de Lemos 3-5, Madrid 28029, Spain. Electronic address: [email protected]. | null | null | null | null | null | null | NLM | eng | null | 10.1016/j.envint.2016.10.015 |
12 | Generic | Centers for Disease Control and Prevention | null | *US Zika Pregnancy and Infant Registry Website | null | Updated May 3, 2018. Accessed July 20, 2018 | null | null | null | null | null | null | null | null | null | null | null | null | *US Zika Pregnancy and Infant Registry Website | null | null | null | null | null | CDC Vital Signs | Zika in Infants | null | null | null | null | null | 10:29 | null | null | null | null | The US Zika Pregnancy and Infant Registry is a collaborative and innovative system to learn about Zika virus infection during pregnancy and after birth. Information from the Registry is used to make recommendations for healthcare providers caring for families affected by Zika virus and plan for needed services. | null | null | https://www.cdc.gov/pregnancy/zika/research/registry.html | null | null | null | null | null | null | null | null | null | null | null |
13 | Generic | DeGrauw, X. T., D., Xu, L., Kancherla, V., DeGrauw, T., | 2,018 | Epidemiology of traumatic brain injury-associated epilepsy and early use of anti-epilepsy drugs: An analysis of insurance claims data, 2004-2014 | null | Epilepsy Res | null | 146 | null | null | 41-49 | null | null | null | 8/3/2018 | 23-07 | null | null | Epidemiology of traumatic brain injury-associated epilepsy and early use of anti-epilepsy drugs: An analysis of insurance claims data, 2004-2014 | Epilepsy research | 0920-1211 | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 10:30 | 30,071,385 | null | null | Anti-epilepsy drug:Early seizure:Epilepsy:Traumatic brain injury | BACKGROUND: About 2.8 million TBI-related emergency department visits, hospitalizations and deaths occurred in 2013 in the United States. Post-traumatic epilepsy (PTE) can be a disabling, life-long outcome of TBI. OBJECTIVES: The purpose of this study is to address the probability of developing PTE within 9 years after TBI, the risk factors associated with PTE, the prevalence of anti-epileptic drug (AEDs) use, and the effectiveness of using AEDs prophylactically after TBI to prevent the development of PTE. METHODS: Using MarketScan(R) databases covering commercial, Medicare Supplemental, and multi-state Medicaid enrollees from 2004 to 2014, we examined the incidence of early seizures (within seven days after TBI) and cumulative incidence of PTE, the hazard ratios (HR) of PTE by age, gender, TBI severity, early seizure and AED use (carbamazepine, clonazepam, divalproex sodium, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, pregabalin, topiramate, acetazolamide). We used backward selection to build the final Cox proportional hazard model and conducted multivariable survival analysis to obtain estimates of crude and adjusted HR (cHRs, aHRs) of PTE and 95% confidence intervals (CI). RESULTS: The incidence of early seizure among TBI patients in our study was 0.5%. The cumulative incidence of PTE increased from 1.0% in one year to 4.0% in nine years. Most patients with TBI (93%) were not prescribed any AED. Gender was not associated with PTE. The risk of PTE was higher for individuals with older age, early seizures, and more severe TBI. Only individuals using prophylactic acetazolamide had significantly lower risk of PTE (aHR = 0.6, CI 0.4-0.9) compared to those not using any AED. CONCLUSION: The probability of developing PTE increased within the study period. The risk of developing PTE significantly increased with age, early seizure and TBI severity. Most of the individuals did not receive AED after TBI. There was no evidence suggesting AEDs helped to prevent PTE with the possible exception of acetazolamide. However, further studies may be needed to test the efficacy of acetazolamide in preventing PTE. | 1872-6844:DeGrauw, Xinyao:Thurman, David:Xu, Likang:Kancherla, Vijaya:DeGrauw, Ton:Journal Article:Netherlands:Epilepsy Res. 2018 Jul 23;146:41-49. doi: 10.1016/j.eplepsyres.2018.07.012. | null | https://www.ncbi.nlm.nih.gov/pubmed/30071385 | Snohomish Health District, 3020 Rucker Ave, Everett, WA, 98201, United States; Rollins School of Public Health, Emory University, 1518 Clifton Rd., Atlanta, GA 30322, United States. Electronic address: [email protected].:Department of Neurology, Emory University, 1648 Pierce Dr. NE, Atlanta, GA 30307 United States.:National Center of Injury Prevention and Control, Centers for Disease Control and Prevention, 4700 Buford Highway, Atlanta, GA 30341, United States.:Rollins School of Public Health, Emory University, 1518 Clifton Rd., Atlanta, GA 30322, United States.:Children's Healthcare of Atlanta, 1405 Clifton Rd, Atlanta, GA 30322, United States; Division of Pediatric Neurology, Emory University, 1405 Clifton Rd, Atlanta, GA 30329. | null | null | null | null | null | null | NLM | eng | null | 10.1016/j.eplepsyres.2018.07.012 |
14 | Generic | Ali, M. K. S., K. R., Laxy, M., Gregg, E. W., | 2,018 | Advancing measurement of diabetes at the population level | null | Curr Diab Rep | null | 18 | null | 11 | 108 | null | null | null | 9/21/2018 | 19-09 | null | null | Advancing measurement of diabetes at the population level | Current diabetes reports | 1534-4827 | null | null | null | CDC Authored Publications | Chronic Diseases and Conditions | null | null | null | null | null | 10:37 | 30,232,630 | null | null | Burden estimation: Diabetes: Nutrition: Quality of life: Surveillance | PURPOSE: The measurement and estimation of diabetes in populations guides resource allocation, health priorities, and can influence practice and future research. To provide a critical reflection on current diabetes surveillance, we provide in-depth discussion about how upstream determinants, prevalence, incidence, and downstream impacts of diabetes are measured in the USA, and the challenges in obtaining valid, accurate, and precise estimates. FINDINGS: Current estimates of the burden of diabetes risk are obtained through national surveys, health systems data, registries, and administrative data. Several methodological nuances influence accurate estimates of the population-level burden of diabetes, including biases in selection and response rates, representation of population subgroups, accuracy of reporting of diabetes status, variation in biochemical testing, and definitions of diabetes used by investigators. Technological innovations and analytical approaches (e.g., data linkage to outcomes data like the National Death Index) may help address some, but not all, of these concerns, and additional methodological advances and validation are still needed. Current surveillance efforts are imperfect, but measures consistently collected and analyzed over several decades enable useful comparisons over time. In addition, we proposed that focused subsampling, use of technology, data linkages, and innovative sensitivity analyses can substantially advance population-level estimation. | 1539-0829: Ali, Mohammed K: Siegel, Karen R: Laxy, Michael: Gregg, Edward W: Journal Article: Review: United States: Curr Diab Rep. 2018 Sep 19;18(11):108. doi: 10.1007/s11892-018-1088-z. | null | https://www.ncbi.nlm.nih.gov/pubmed/30232630 | Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA. [email protected].: Hubert Department of Global Health, Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA, 30322, USA. [email protected].: Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, GA, USA. [email protected].: Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.: Hubert Department of Global Health, Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA, 30322, USA.: Helmholtz Zentrum Munchen, Institute of Health Economics and Health Care Management, Munich, Germany. | null | null | null | null | null | null | NLM | eng | null | 10.1007/s11892-018-1088-z |
15 | Generic | Henley, S. J. G., S., Singh, S. D., O'Neil, M. E., Buchanan Lunsford, N., Momin, B., Richards, T. B., | 2,018 | Lung cancer among women in the United States | null | J Womens Health (Larchmt) | null | null | null | null | null | null | null | null | 10/13/2018 | 10-Dec | null | null | Lung cancer among women in the United States | Journal of women's health (2002) | 1540-9996 | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 10:41 | 30,312,110 | null | null | National Comprehensive Cancer Control Program: National Program of Cancer Registries: U.S. Cancer Statistics: cancer prevention: cancer survivorship: early detection: lung cancer: women's health | November marks Lung Cancer Awareness Month, and reminds us that lung cancer is the leading cause of cancer death among women in the United States. In this brief report, we highlight CDC resources that can be used to examine the most recent data on lung cancer incidence, survival, prevalence, and mortality among women. Using the U.S. Cancer Statistics Data Visualizations tool, we report that in 2015, 104,992 new cases of lung cancer and 70,073 lung cancer deaths were reported among women in the United States. The 5-year relative survival among females diagnosed with lung cancer was 22%, and as of 2015, approximately 185,759 women were living with a lung cancer diagnosis. We also describe ways CDC works to collect and disseminate quality cancer surveillance data, prevent initiation of tobacco use, promote cessation, eliminate exposure to secondhand smoke, identify and eliminate disparities, promote lung cancer screening, and help cancer survivors live longer by improving health outcomes. | 1931-843x: Henley, S Jane: Gallaway, Shayne: Singh, Simple D: O'Neil, Mary Elizabeth: Buchanan Lunsford, Natasha: Momin, Behnoosh: Richards, Thomas B: Journal Article: United States: J Womens Health (Larchmt). 2018 Oct 12. doi: 10.1089/jwh.2018.7397. | null | https://www.ncbi.nlm.nih.gov/pubmed/30312110 | Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention , Atlanta, Georgia . | null | null | null | null | null | null | NLM | eng | null | 10.1089/jwh.2018.7397 |
16 | Generic | Andes, L. J. C., Y. J.;Rolka, D. B.;Gregg, E. W.;Imperatore, G. | 2,019 | Prevalence of prediabetes among adolescents and young adults in the United States, 2005-2016 | null | JAMA Pediatr | null | null | null | null | e194498 | null | null | null | 12/4/2019 | 12-Feb | null | null | Prevalence of prediabetes among adolescents and young adults in the United States, 2005-2016 | null | 2168-6203 | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 12:01 | 31,790,544 | null | null | null | Importance: Individuals with prediabetes are at increased risk of developing type 2 diabetes, chronic kidney disease, and cardiovascular disease. The incidence and prevalence of type 2 diabetes in the US adolescent population have increased in the last decade. Therefore, it is important to monitor the prevalence of prediabetes and varying levels of glucose tolerance to assess the future risk of type 2 diabetes in the youngest segment of the population. Objective: To examine the prevalence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and increased glycated hemoglobin A1c (HbA1c) levels in US adolescents (aged 12-18 years) and young adults (aged 19-34 years) without diabetes. Design, Setting, and Participants: This cross-sectional analyses of the 2005-2016 National Health and Nutrition Examination Survey assessed a population-based sample of adolescents and young adults who were not pregnant, did not have diabetes, and had measured fasting plasma glucose, 2-hour plasma glucose after a 75-g oral glucose tolerance test, and HbA1c levels. Analysis began in April 2017. Main Outcomes and Measures: Impaired fasting glucose was defined as fasting plasma glucose of 100 mg/dL to less than 126 mg/dL, IGT as 2-hour plasma glucose of 140 mg/dL to less than 200 mg/dL, and increased HbA1c level as HbA1c level between 5.7% and 6.4%. The prevalence of IFG, isolated IFG, IGT, isolated IGT, increased HbA1c level, isolated increased HbA1c level, and prediabetes (defined as having IFG, IGT, or increased HbA1c level) were estimated. Fasting insulin levels and cardiometabolic risk factors across glycemic abnormality phenotypes were also compared. Obesity was defined as having age- and sex-specific body mass index (calculated as weight in kilograms divided by height in meters squared) in the 95th percentile or higher in adolescents or 30 or higher in young adults. Results: Of 5786 individuals, 2606 (45%) were adolescents and 3180 (55%) were young adults. Of adolescents, 50.6% (95% CI, 47.6%-53.6%) were boys, and 50.6% (95% CI, 48.8%-52.4%) of young adults were men. Among adolescents, the prevalence of prediabetes was 18.0% (95% CI, 16.0%-20.1%) and among young adults was 24.0% (95% CI, 22.0%-26.1%). Impaired fasting glucose constituted the largest proportion of prediabetes, with prevalence of 11.1% (95% CI, 9.5%-13.0%) in adolescents and 15.8% (95% CI, 14.0%-17.9%) in young adults. In multivariable logistic models including age, sex, race/ethnicity, and body mass index, the predictive marginal prevalence of prediabetes was significantly higher in male than in female individuals (22.5% [95% CI, 19.5%-25.4%] vs 13.4% [95% CI, 10.8%-16.5%] in adolescents and 29.1% [95% CI, 26.4%-32.1%] vs 18.8% [95% CI, 16.5%-21.3%] in young adults). Prediabetes prevalence was significantly higher in individuals with obesity than in those with normal weight (25.7% [95% CI, 20.0%-32.4%] vs 16.4% [95% CI, 14.3%-18.7%] in adolescents and 36.9% [95% CI, 32.9%-41.1%] vs 16.6% [95% CI, 14.2%-19.4%] in young adults). Compared with persons with normal glucose tolerance, adolescents and young adults with prediabetes had significantly higher non-high-density lipoprotein cholesterol levels, systolic blood pressure, central adiposity, and lower insulin sensitivity (P < .05 for all). Conclusions and Relevance: In the United States, about 1 of 5 adolescents and 1 of 4 young adults have prediabetes. The adjusted prevalence of prediabetes is higher in male individuals and in people with obesity. Adolescents and young adults with prediabetes also present an unfavorable cardiometabolic risk profile, putting them both at increased risk of type 2 diabetes and cardiovascular diseases. | 2168-6211:Andes, Linda J:Cheng, Yiling J:Rolka, Deborah B:Gregg, Edward W:Imperatore, Giuseppina:Journal Article:United States:JAMA Pediatr. 2019 Dec 2:e194498. doi: 10.1001/jamapediatrics.2019.4498. | null | https://www.ncbi.nlm.nih.gov/pubmed/31790544 | National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia.:Department of Public Health and Epidemiology, Imperial College London, London, United Kingdom. | null | null | null | null | null | null | NLM | eng | null | 10.1001/jamapediatrics.2019.4498 |
17 | Generic | Ritchey, M. D. M., S.;McNeely, J.;Shaffer, T.;Jackson, S. L.;Keteyian, S. J.;Brawner, C. A.;Whooley, M. A.;Chang, T.;Stolp, H.;Schieb, L.;Wright, J. | 2,020 | Tracking cardiac rehabilitation participation and completion among Medicare beneficiaries to inform the efforts of a national initiative | null | Circ Cardiovasc Qual Outcomes | null | 13 | null | 1 | e005902 | null | null | null | 1/15/2020 | Jan | null | null | Tracking cardiac rehabilitation participation and completion among Medicare beneficiaries to inform the efforts of a national initiative | null | 1941-7713 | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 12:03 | 31,931,615 | null | null | cardiac rehabilitation:coronary artery bypass:heart diseases:myocardial infarction:percutaneous coronary intervention | BACKGROUND: Despite cardiac rehabilitation (CR) being shown to improve health outcomes among patients with heart disease, its use has been suboptimal. In response, the Million Hearts Cardiac Rehabilitation Collaborative developed a road map to improve CR use, including increasing participation rates to >/=70% by 2022. This observational study provides current estimates to measure progress and identifies the populations and regions most at risk for CR service underutilization. METHODS AND RESULTS: We identified Medicare fee-for-service beneficiaries who were CR eligible in 2016, and assessed CR participation (>/=1 CR session attended), timely initiation (participation within 21 days of event), and completion (>/=36 sessions attended) through 2017. Measures were assessed overall, by beneficiary characteristics and geography, and by primary CR-qualifying event type (acute myocardial infarction hospitalization; coronary artery bypass surgery; heart valve repair/replacement; percutaneous coronary intervention; or heart/heart-lung transplant). Among 366 103 CR-eligible beneficiaries, 89 327 (24.4%) participated in CR, of whom 24.3% initiated within 21 days and 26.9% completed CR. Eligibility was highest in the East South Central Census Division (14.8 per 1000). Participation decreased with increasing age, was lower among women (18.9%) compared with men (28.6%; adjusted prevalence ratio: 0.91 [95% CI, 0.90-0.93]) was lower among Hispanics (13.2%) and non-Hispanic blacks (13.6%) compared with non-Hispanic whites (25.8%; adjusted prevalence ratio: 0.63 [0.61-0.66] and 0.70 [0.67-0.72], respectively), and varied by hospital referral region and Census Division (range: 18.6% [East South Central] to 39.1% [West North Central]) and by qualifying event type (range: 7.1% [acute myocardial infarction without procedure] to 55.3% [coronary artery bypass surgery only]). Timely initiation varied by geography and qualifying event type; completion varied by geography. CONCLUSIONS: Only 1 in 4 CR-eligible Medicare beneficiaries participated in CR and marked disparities were observed. Reinforcement of current effective strategies and development of new strategies will be critical to address the noted disparities and achieve the 70% participation goal. | 1941-7705:Ritchey, Matthew D:Maresh, Sha:McNeely, Jessica:Shaffer, Thomas:Jackson, Sandra L:Keteyian, Steven J:Brawner, Clinton A:Whooley, Mary A:Chang, Tiffany:Stolp, Haley:Schieb, Linda:Wright, Janet:Journal Article:United States:Circ Cardiovasc Qual Outcomes. 2020 Jan;13(1):e005902. doi: 10.1161/CIRCOUTCOMES.119.005902. Epub 2020 Jan 14. | null | https://www.ncbi.nlm.nih.gov/pubmed/31931615 | Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, GA (M.D.R., S.L.J., T.C., H.S., L.S.).:Center for Medicare and Medicaid Innovation, Centers for Medicare and Medicaid Services, Baltimore, MD (S.M., J.M., T.S.).:Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan (S.J.K., C.A.B.).:School of Medicine, University of California, San Francisco (M.W.).:IHRC, Inc. (T.C., H.S.).:Office of the Surgeon General, US Department of Health and Human Services, Washington, DC (J.W.). | null | null | null | null | null | null | NLM | eng | null | 10.1161/circoutcomes.119.005902 |
18 | Generic | P. H. Charoenwoodhipong, S. D.;Marder, W.;Hassett, A. L.;McCune, W. J.;Gordon, C.;Helmick, C. G.;Barbour, K. E.;Wang, L.;Mancuso, P.;Somers, E. C.;Zick, S. M. | 2,020 | Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology and Surveillance Program | null | Arthritis Care Res (Hoboken) | null | 72 | null | 7 | 874-881 | null | null | null | 5/11/2019 | Jul | null | null | Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology and Surveillance Program | null | 2151-464X (Print):2151-464x | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 12:25 | 31,074,595 | null | null | null | OBJECTIVE: To examine associations between dietary intake of omega-3 (n-3; generally antiinflammatory) and omega-6 (n-6; generally proinflammatory) fatty acids and patient-reported outcomes in systemic lupus erythematosus (SLE). METHODS: This study was based on the population-based Michigan Lupus Epidemiology and Surveillance cohort. Estimates of n-3 and n-6 intake were derived from Diet History Questionnaire II items (past year with portion size version). Patient-reported outcomes included self-reported lupus activity (Systemic Lupus Activity Questionnaire [SLAQ]). Multivariable regression, adjusted for age, sex, race, and body mass index, was used to assess associations between absolute intake of n-3 and n-6, as well as the n-6:n-3 ratio, and patient-reported outcomes. RESULTS: Among 456 SLE cases, 425 (93.2%) were female, 207 (45.4%) were African American, and the mean ± SD age was 52.9 ± 12.3 years. Controlling for potential confounders, the average SLAQ score was significantly higher by 0.3 points (95% confidence interval [95% CI] 0.1, 0.6; P = 0.013) with each unit increase of the n-6:n-3 ratio. Both lupus activity and Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance scores were lower with each 1-gram/1,000 kcal increase of n-3 fatty acids (SLAQ regression coefficient ? = -0.8 [95% CI -1.6, 0.0]; P = 0.055; PROMIS sleep ? = -1.1 [95% CI -2.0, -0.2]; P = 0.017). Higher n-3 intakes were nonsignificantly associated with lower levels of depressive symptoms and comorbid fibromyalgia, and with higher quality of life, whereas results for the n6:n3 ratio trended in the opposite direction. CONCLUSION: This population-based study suggests that higher dietary intake of n-3 fatty acids and lower n-6:n-3 ratios are favorably associated with patient-reported outcomes in SLE, particularly self-reported lupus activity and sleep quality. | 2151-4658:Charoenwoodhipong, Prae:Harlow, Sioban D:Marder, Wendy:Orcid: 0000-0001-7963-4206:Hassett, Afton L:McCune, W Joseph:Gordon, Caroline:Helmick, Charles G:Barbour, Kamil E:Wang, Lu:Mancuso, Peter:Somers, Emily C:Orcid: 0000-0001-5234-3978:Zick, Suzanna M:UL1RR024986/RR/NCRR NIH HHS/United States:K01 ES019909/ES/NIEHS NIH HHS/United States:1U01 DP006265/CC/CDC HHS/United States:Royal Thai Government Scholarship/:K01ES019909/ES/NIEHS NIH HHS/United States:P30 ES017885/ES/NIEHS NIH HHS/United States:P30ES017885/ES/NIEHS NIH HHS/United States:UL1 TR002240/TR/NCATS NIH HHS/United States:P30 DK020572/DK/NIDDK NIH HHS/United States:U58 CCU522826/CC/CDC HHS/United States:U01 DP003250/DP/NCCDPHP CDC HHS/United States:1U01 DP003250/CC/CDC HHS/United States:U01 DP006265/DP/NCCDPHP CDC HHS/United States:U58 DP001441/CC/CDC HHS/United States:U58 DP001441/DP/NCCDPHP CDC HHS/United States:U01 DP006489/DP/NCCDPHP CDC HHS/United States:UL1 RR024986/RR/NCRR NIH HHS/United States:Journal Article:Arthritis Care Res (Hoboken). 2020 Jul;72(7):874-881. doi: 10.1002/acr.23925. | null | https://www.ncbi.nlm.nih.gov/pubmed/31074595 | University of Michigan, Ann Arbor.:University of Birmingham, Birmingham, UK.:Centers for Disease Control and Prevention, Atlanta, Georgia. | null | null | null | null | null | null | null | eng | null | 10.1002/acr.23925 |
19 | Generic | Adams, R. J. M., V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., et al, | 1,998 | Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography | null | N Engl J Med | null | 339 | null | 1 | 44692 | null | null | null | 7/2/1998 | 7-Feb | null | null | Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography | The New England journal of medicine | 0028-4793 (Print): 0028-4793 | null | null | null | Key Scientific Articles in Featured Topic Areas | Sickle Cell Disease | null | null | null | null | null | null | 9,647,873 | null | null | Adolescent: Anemia, Sickle Cell/complications/physiopathology/*therapy/ultrasonography: Blood Flow Velocity: *Blood Transfusion: Cerebral Hemorrhage/epidemiology/etiology: Cerebral Infarction/epidemiology/etiology: Cerebrovascular Circulation: Cerebrovascular Disorders/etiology/*prevention & control: Child: Child, Preschool: Disease-Free Survival: Female: Hemoglobin, Sickle/analysis: Humans: Incidence: Male: Risk: Ultrasonography, Doppler, Transcranial | BACKGROUND: Blood transfusions prevent recurrent stroke in children with sickle cell anemia, but the value of transfusions in preventing a first stroke is unknown. We used transcranial Doppler ultrasonography to identify children with sickle cell anemia who were at high risk for stroke and then randomly assigned them to receive standard care or transfusions to prevent a first stroke. METHODS: To enter the study, children with sickle cell anemia and no history of stroke had to have undergone two transcranial Doppler studies that showed that the time-averaged mean blood-flow velocity in the internal carotid or middle cerebral artery was 200 cm per second or higher. The patients were randomly assigned to receive standard care or transfusions to reduce the hemoglobin S concentration to less than 30 percent of the total hemoglobin concentration. The incidence of stroke (cerebral infarction or intracranial hemorrhage) was compared between the two groups. RESULTS: A total of 130 children (mean [+/-SD] age, 8.3+/-3.3 years) were enrolled; 63 were randomly assigned to receive transfusions and 67 to receive standard care. At base line, the transfusion group had a slightly lower mean hemoglobin concentration (7.2 vs. 7.6 g per deciliter, P=0.001) and hematocrit (20.4 vs. 21.7 percent, P=0.002). Ten patients dropped out of the transfusion group, and two patients crossed over from the standard-care group to the transfusion group. There were 10 cerebral infarctions and 1 intracerebral hematoma in the standard-care group, as compared with 1 infarction in the transfusion group -- a 92 percent difference in the risk of stroke (P<0.001). This result led to the early termination of the trial. CONCLUSIONS: Transfusion greatly reduces the risk of a first stroke in children with sickle cell anemia who have abnormal results on transcranial Doppler ultrasonography. | Adams, R J: McKie, V C: Hsu, L: Files, B: Vichinsky, E: Pegelow, C: Abboud, M: Gallagher, D: Kutlar, A: Nichols, F T: Bonds, D R: Brambilla, D: U10 HL 52016/HL/NHLBI NIH HHS/United States: U10 HL 52193/HL/NHLBI NIH HHS/United States: Clinical Trial: Journal Article: Multicenter Study: Randomized Controlled Trial: Research Support, U.S. Gov't, P.H.S.: United States: N Engl J Med. 1998 Jul 2;339(1):5-11. | null | http://www.ncbi.nlm.nih.gov/pubmed/9647873/?otool=cdciclib | Department of Neurology, Medical College of Georgia, Augusta 30912-3200, USA. | null | null | null | null | null | null | NLM | Eng | null | 10.1056/nejm199807023390102 |
20 | Generic | Crider, K. S. D., O., Hao, L., Dowling, N. F., Li, S., Molloy, A. M., Li, Z., Zhu, J., Berry, R. J., | 2,014 | Population red blood cell folate concentrations for prevention of neural tube defects: Bayesian model | null | Bmj | null | 349 | null | null | g4554 | null | null | null | 7/31/2014 | 29-07 | null | null | Population red blood cell folate concentrations for prevention of neural tube defects: Bayesian model | BMJ (Clinical research ed.) | 0959-535x | null | null | null | CDC Public Health Grand Rounds | Maternal and Child Health - Global Prevention of Neural Tube Defects | null | null | null | null | null | 9:41 | 25,073,783 | null | null | Bayes Theorem: Erythrocytes/*chemistry: Female: Folic Acid/administration & dosage/*metabolism: Folic Acid Deficiency/diet therapy/genetics/prevention & control: Genotype: Hematinics/administration & dosage: Humans: Methylenetetrahydrofolate Reductase (NADPH2)/genetics: Neural Tube Defects/diet therapy/genetics/*prevention & control: Pregnancy: Prenatal Care/methods: Prospective Studies: Randomized Controlled Trials as Topic | OBJECTIVE: To determine an optimal population red blood cell (RBC) folate concentration for the prevention of neural tube birth defects. DESIGN: Bayesian model. SETTING: Data from two population based studies in China. PARTICIPANTS: 247,831 participants in a prospective community intervention project in China (1993-95) to prevent neural tube defects with 400 mug/day folic acid supplementation and 1194 participants in a population based randomized trial (2003-05) to evaluate the effect of folic acid supplementation on blood folate concentration among Chinese women of reproductive age. INTERVENTION: Folic acid supplementation (400 mug/day). MAIN OUTCOME MEASURES: Estimated RBC folate concentration at time of neural tube closure (day 28 of gestation) and risk of neural tube defects. RESULTS: Risk of neural tube defects was high at the lowest estimated RBC folate concentrations (for example, 25.4 (95% uncertainty interval 20.8 to 31.2) neural tube defects per 10,000 births at 500 nmol/L) and decreased as estimated RBC folate concentration increased. Risk of neural tube defects was substantially attenuated at estimated RBC folate concentrations above about 1000 nmol/L (for example, 6 neural tube defects per 10,000 births at 1180 (1050 to 1340) nmol/L). The modeled dose-response relation was consistent with the existing literature. In addition, neural tube defect risk estimates developed using the proposed model and population level RBC information were consistent with the prevalence of neural tube defects in the US population before and after food fortification with folic acid. CONCLUSIONS: A threshold for "optimal" population RBC folate concentration for the prevention of neural tube defects could be defined (for example, approximately 1000 nmol/L). Population based RBC folate concentrations, as a biomarker for risk of neural tube defects, can be used to facilitate evaluation of prevention programs as well as to identify subpopulations at elevated risk for a neural tube defect affected pregnancy due to folate insufficiency. | 1756-1833: Crider, Krista S: Devine, Owen: Hao, Ling: Dowling, Nicole F: Li, Song: Molloy, Anne M: Li, Zhu: Zhu, Jianghui: Berry, Robert J: Journal Article: Research Support, U.S. Gov't, P.H.S.: England: BMJ. 2014 Jul 29;349:g4554. doi: 10.1136/bmj.g4554. | null | http://www.ncbi.nlm.nih.gov/pubmed/25073783 | National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA [email protected].: National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.: Peking University Health Science Center, Peking University, Beijing, China US Centers for Disease Control and Prevention, US Embassy, Beijing, China.: Peking University Third Hospital, Beijing, China.: School of Medicine, Trinity College, Dublin, Ireland.: Peking University Health Science Center, Peking University, Beijing, China.: Peking University Health Science Center, Peking University, Beijing, China Division of Risk Assessment, China National Center for Food Safety Risk Assessment, Beijing, China. | null | null | null | null | null | null | NLM | eng | null | 10.1136/bmj.g4554 |
21 | Generic | Campbell, E. M. J., H., Shankar, A., Hanson, D., Luo, W., Masciotra, S., Owen, S. M., Oster, A. M., Galang, R. R., Spiller, M. W., Blosser, S. J., Chapman, E., Roseberry, J. C., Gentry, J., Pontones, P., Duwve, J., Peyrani, P., Kagan, R. M., Whitcomb, J. M., Peters, P. J., Heneine, W., Brooks, J. T., Switzer, W. M., | 2,017 | Detailed transmission network analysis of a large opiate-driven outbreak of HIV infection in the United States | null | J Infect Dis | null | null | null | null | null | null | null | null | 10/14/2017 | 10-May | null | null | Detailed transmission network analysis of a large opiate-driven outbreak of HIV infection in the United States | The Journal of infectious diseases | 0022-1899 | null | null | null | Top Articles of the Week | Communicable Diseases | null | null | null | null | null | 9:43 | 29,029,156 | null | null | HIV outbreak:Pwid:phylodynamic:transactional sex:transmission network | In January 2015, an outbreak of undiagnosed human immunodeficiency virus (HIV) infections among persons who inject drugs (PWID) was recognized in rural Indiana. By September 2016, 205 persons in this community of approximately 4400 had received a diagnosis of HIV infection. We report results of new approaches to analyzing epidemiologic and laboratory data to understand transmission during this outbreak. HIV genetic distances were calculated using the polymerase region. Networks were generated using data about reported high-risk contacts, viral genetic similarity, and their most parsimonious combinations. Sample collection dates and recency assay results were used to infer dates of infection. Epidemiologic and laboratory data each generated large and dense networks. Integration of these data revealed subgroups with epidemiologic and genetic commonalities, one of which appeared to contain the earliest infections. Predicted infection dates suggest that transmission began in 2011, underwent explosive growth in mid-2014, and slowed after the declaration of a public health emergency. Results from this phylodynamic analysis suggest that the majority of infections had likely already occurred when the investigation began and that early transmission may have been associated with sexual activity and injection drug use. Early and sustained efforts are needed to detect infections and prevent or interrupt rapid transmission within networks of uninfected PWID. | 1537-6613:Campbell, Ellsworth M:Jia, Hongwei:Shankar, Anupama:Hanson, Debra:Luo, Wei:Masciotra, Silvina:Owen, S Michele:Oster, Alexandra M:Galang, Romeo R:Spiller, Michael W:Blosser, Sara J:Chapman, Erika:Roseberry, Jeremy C:Gentry, Jessica:Pontones, Pamela:Duwve, Joan:Peyrani, Paula:Kagan, Ron M:Whitcomb, Jeannette M:Peters, Philip J:Heneine, Walid:Brooks, John T:Switzer, William M:Journal Article:United States:J Infect Dis. 2017 Oct 5. doi: 10.1093/infdis/jix307. | null | http://www.ncbi.nlm.nih.gov/pubmed/29029156 | Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.:Indiana State Department of Health.:Indiana University Richard M. Fairbanks School of Public Health, Indianapolis.:Division of Infectious Diseases, University of Louisville, Kentucky.:Quest Diagnostics, Madison, New Jersey.:LabCorp, Burlington, North Carolina. | null | null | null | null | null | null | NLM | eng | null | 10.1093/infdis/jix307 |
22 | Generic | Charles, M. R., M., Joseph, P., Bury, M. R., Perrin, G., Louis, F. J., Fitter, D. L., Marston, B. J., Deyde, V., Boncy, J., Morose, W., Pape, J. W., Lowrance, D. W., | 2,017 | Trends in tuberculosis case notification and treatment success, Haiti, 2010-2015 | null | Am J Trop Med Hyg | null | null | 97 | null | 4_Suppl | 49-56 | null | null | 10/25/2017 | Oct | null | null | Trends in tuberculosis case notification and treatment success, Haiti, 2010-2015 | The American journal of tropical medicine and hygiene | 0002-9637 | null | null | null | Top Articles of the Week | Communicable Diseases | null | null | null | null | null | 9:44 | 29,064,365 | null | null | null | Since the 2010 earthquake, tuberculosis (TB) control has been a major priority for health sector response and recovery efforts in Haiti. The goal of this study was to analyze trends in TB case notification in Haiti from the aggregate data reported by the National TB Control Program to understand the effects of such efforts. A total of 95,745 TB patients were registered for treatment in Haiti between 2010 and 2015. Three regions, the West, Artibonite, and North departments accounted for 68% of the TB cases notified during the period. Patients in the 15-34 age groups represented 53% (50,560) of all cases. Case notification rates of all forms of TB increased from 142.7/100,000 in 2010 to 153.4 in 2015, peaking at 163.4 cases/100,000 in 2013. Case notification for smear-positive pulmonary TB increased from 85.5 cases/100,000 to 105.7 cases/100,000, whereas treatment success rates remained stable at 79-80% during the period. Active TB case finding efforts in high-risk communities and the introduction of new diagnostics have contributed to increasing TB case notification trends in Haiti from 2010 to 2015. Targeted interventions and novel strategies are being implemented to reach high-risk populations and underserved communities. | 1476-1645:Charles, Macarthur:Richard, Milo:Joseph, Patrice:Bury, Margarette R:Perrin, Georges:Louis, Frantz Jean:Fitter, David L:Marston, Barbara J:Deyde, Varough:Boncy, Jacques:Morose, Willy:Pape, Jean W:Lowrance, David W:Journal Article:United States:Am J Trop Med Hyg. 2017 Oct;97(4_Suppl):49-56. doi: 10.4269/ajtmh.16-0863. | null | http://www.ncbi.nlm.nih.gov/pubmed/29064365/?otool=cdciclib | Centers for Disease Control and Prevention, Port-au-Prince, Haiti.:Programme National de Lutte contre la Tuberculose, Ministere de la Sante Publique et de la Population, Port-au-Prince, Haiti.:Les Centres GHESKIO, Port-au-Prince, Haiti.:Pan American Health Organization/World Health Organization, Port-au-Prince, Haiti.:Laboratoire National de Sante Publique, Ministere de la Sante Publique et de la Population, Port-au-Prince, Haiti. | null | null | null | null | null | PubMed | NLM | eng | null | 10.4269/ajtmh.16-0863 |
23 | Generic | Mardon, R. M., D., Nooney, J., Campione, J., Jenkins, F., Johnson, M., Merrill, L., Rolka, D. B., Saydah, S., Geiss, L. S., Zhang, X., Shrestha, S., | 2,017 | Novel methods and data sources for surveillance of state-level diabetes and prediabetes prevalence | null | Prev Chronic Dis | null | 14 | null | null | E106 | null | null | null | 11/5/2017 | 11-Feb | null | null | Novel methods and data sources for surveillance of state-level diabetes and prediabetes prevalence | Preventing chronic disease | 1545-1151 | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 9:46 | 29,101,768 | null | null | null | States bear substantial responsibility for addressing the rising rates of diabetes and prediabetes in the United States. However, accurate state-level estimates of diabetes and prediabetes prevalence that include undiagnosed cases have been impossible to produce with traditional sources of state-level data. Various new and nontraditional sources for estimating state-level prevalence are now available. These include surveys with expanded samples that can support state-level estimation in some states and administrative and clinical data from insurance claims and electronic health records. These sources pose methodologic challenges because they typically cover partial, sometimes nonrandom subpopulations; they do not always use the same measurements for all individuals; and they use different and limited sets of variables for case finding and adjustment. We present an approach for adjusting new and nontraditional data sources for diabetes surveillance that addresses these limitations, and we present the results of our proposed approach for 2 states (Alabama and California) as a proof of concept. The method reweights surveys and other data sources with population undercoverage to make them more representative of state populations, and it adjusts for nonrandom use of laboratory testing in clinically generated data sets. These enhanced diabetes and prediabetes prevalence estimates can be used to better understand the total burden of diabetes and prediabetes at the state level and to guide policies and programs designed to prevent and control these chronic diseases. | 1545-1151:Mardon, Russ:Marker, David:Nooney, Jennifer:Campione, Joanne:Jenkins, Frank:Johnson, Maurice:Merrill, Lori:Rolka, Deborah B:Saydah, Sharon:Geiss, Linda S:Zhang, Xuanping:Shrestha, Sundar:Journal Article:United States:Prev Chronic Dis. 2017 Nov 2;14:E106. doi: 10.5888/pcd14.160572. | null | http://www.ncbi.nlm.nih.gov/pubmed/29101768 | Westat, Inc, 1600 Research Blvd, RB 1170, Rockville, MD 20850. Email: [email protected].:Westat, Inc, Rockville, Maryland.:Centers for Disease Control and Prevention, Atlanta, Georgia. | null | null | null | null | null | null | NLM | eng | null | 10.5888/pcd14.160572 |
24 | Generic | Branson, B. M. H., H. H., Lampe, M. A., Janssen, R. S., Taylor, A. W., Lyss, S. B., Clark, J. E., | 2,006 | *Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings | null | MMWR Recomm Rep | null | null | 55 | null | Rr-14 | 44578 | null | null | 9/22/2006 | 22-09 | null | null | *Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings | MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports | 1057-5987 | null | null | null | CDC Vital Signs | Communicable Diseases | null | null | null | null | null | 9:47 | 16,988,643 | null | null | AIDS Serodiagnosis/*standards:Adolescent:Adult:Diagnostic Tests, Routine/standards:Female:HIV Infections/*prevention & control:Health Facilities/standards:Health Policy:Humans:Male:Mass Screening/standards:Pregnancy:United States:Health Care and Public Health | These recommendations for human immunodeficiency virus (HIV) testing are intended for all health-care providers in the public and private sectors, including those working in hospital emergency departments, urgent care clinics, inpatient services, substance abuse treatment clinics, public health clinics, community clinics, correctional health-care facilities, and primary care settings. The recommendations address HIV testing in health-care settings only. They do not modify existing guidelines concerning HIV counseling, testing, and referral for persons at high risk for HIV who seek or receive HIV testing in nonclinical settings (e.g., community-based organizations, outreach settings, or mobile vans). The objectives of these recommendations are to increase HIV screening of patients, including pregnant women, in health-care settings; foster earlier detection of HIV infection; identify and counsel persons with unrecognized HIV infection and link them to clinical and prevention services; and further reduce perinatal transmission of HIV in the United States. These revised recommendations update previous recommendations for HIV testing in health-care settings and for screening of pregnant women (CDC. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings. MMWR 1993;42[No. RR-2]:1-10; CDC. Revised guidelines for HIV counseling, testing, and referral. MMWR 2001;50[No. RR-19]:1-62; and CDC. Revised recommendations for HIV screening of pregnant women. MMWR 2001;50[No. RR-19]:63-85). Major revisions from previously published guidelines are as follows: For patients in all health-care settings HIV screening is recommended for patients in all health-care settings after the patient is notified that testing will be performed unless the patient declines (opt-out screening). Persons at high risk for HIV infection should be screened for HIV at least annually. Separate written consent for HIV testing should not be required; general consent for medical care should be considered sufficient to encompass consent for HIV testing. Prevention counseling should not be required with HIV diagnostic testing or as part of HIV screening programs in health-care settings. For pregnant women HIV screening should be included in the routine panel of prenatal screening tests for all pregnant women. HIV screening is recommended after the patient is notified that testing will be performed unless the patient declines (opt-out screening). Separate written consent for HIV testing should not be required; general consent for medical care should be considered sufficient to encompass consent for HIV testing. Repeat screening in the third trimester is recommended in certain jurisdictions with elevated rates of HIV infection among pregnant women. | 1545-8601:Branson, Bernard M:Handsfield, H Hunter:Lampe, Margaret A:Janssen, Robert S:Taylor, Allan W:Lyss, Sheryl B:Clark, Jill E:Centers for Disease Control and Prevention (CDC):Journal Article:Practice Guideline:United States:MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17; quiz CE1-4. | null | http://www.ncbi.nlm.nih.gov/pubmed/16988643 | Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed), Atlanta, GA 30333, USA. [email protected] | null | null | null | null | null | null | NLM | eng | null | null |
25 | Generic | Armstead, T. L. K., M., Rambo, K., Estefan, L. F., Dills, J., Rivera, M. S., El-Beshti, R., | 2,018 | The use of the Data-to-Action Framework in the evaluation of CDC's DELTA FOCUS Program | null | J Public Health Manag Pract | null | null | null | null | S51-s58 | null | null | null | 12/1/2017 | Jan/Feb | null | null | The use of the Data-to-Action Framework in the evaluation of CDC's DELTA FOCUS Program | Journal of public health management and practice : JPHMP | 1078-4659 | null | null | null | Top Ten Articles of the Week | Injury and Violence | null | null | null | null | null | 9:49 | 29,189,504 | null | null | null | The Centers for Disease Control and Prevention's (CDC's) Domestic Violence Prevention Enhancements and Leadership Through Alliances, Focusing on Outcomes for Communities United with States (DELTA FOCUS) program is a 5-year cooperative agreement (2013-2018) funding 10 state domestic violence coalitions and local coordinated community response teams to engage in primary prevention of intimate partner violence. Grantees' prevention strategies were often developmental and emergent; therefore, CDC's approach to program oversight, administration, and support to grantees required a flexible approach. CDC staff adopted a Data-to-Action Framework for the DELTA FOCUS program evaluation that supported a culture of learning to meet dynamic and unexpected information needs. Briefly, a Data-to-Action Framework involves the collection and use of information in real time for program improvement. Utilizing this framework, the DELTA FOCUS data-to-action process yielded important insights into CDC's ongoing technical assistance, improved program accountability by providing useful materials, and information for internal agency leadership, and helped build a learning community among grantees. CDC and other funders, as decision makers, can promote program improvements that are data-informed by incorporating internal processes supportive of ongoing data collection and review. | 1550-5022:Armstead, Theresa L:Kearns, Megan:Rambo, Kirsten:Estefan, Lianne Fuino:Dills, Jenny:Rivera, Moira S:El-Beshti, Rasha:Journal Article:United States:J Public Health Manag Pract. 2018 Jan/Feb;24 Suppl 1 Supplement, Injury and Violence Prevention:S51-S58. doi: 10.1097/PHH.0000000000000677. | null | https://www.ncbi.nlm.nih.gov/pubmed/29189504 | Division of Violence Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia (Drs Armstead, Kearns, Rambo, and Estefan, and Ms Dills); Research and Evaluation Division, Contracting Resources Group, Inc, San Antonio, Texas (Dr Rivera); and Research and Evaluation Division, Contracting Resources Group, Inc, Baltimore, Maryland (Ms El-Beshti). | null | null | null | null | null | Top Ten Articles of the Week | NLM | eng | null | 10.1097/phh.0000000000000677 |
26 | Generic | Ling, J. S., M., Choi, S. H., | 2,018 | Attempts to lose weight among US children: Importance of weight perceptions from self, parents, and health professionals | null | Obesity (Silver Spring) | null | null | null | null | null | null | null | null | 2/2/2018 | 2-Jan | null | null | Attempts to lose weight among US children: Importance of weight perceptions from self, parents, and health professionals | Obesity (Silver Spring, Md.) | 1930-7381 | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 10:05 | 29,388,733 | null | null | null | OBJECTIVE: The objective of this study was to investigate how perceptions of weight by children themselves, parents, and health professionals influence children's persistent attempts to lose weight. METHODS: The sample included 4,914 children aged 8 to 15 years from the 2005 to 2014 National Health and Nutrition Examination Survey (representing 20.7 million children). Data were analyzed using logistic regression models. RESULTS: About 34.2% never made an effort to lose weight, whereas 28.2% made persistent attempts to lose weight. Children's persistent attempts to lose weight were highly related to their own BMI percentile. Children's self-perceptions of overweight increased the odds of persistent attempts to lose weight more than sevenfold. Health professionals' perceptions that children were overweight increased the odds of persistent attempts to lose weight almost threefold. However, parents' perceptions of children as overweight had a relatively small though significant influence on children's attempts to lose weight. CONCLUSIONS: As perceptions of children's weight status play big roles in children's attempts to lose weight, interventions focusing on increasing accuracy of perceptions may help promote healthy weight loss efforts. Although parents are key agents in controlling their children's weight gain, especially among minority school-aged children, the study findings also emphasize the greater importance of health professionals on children's attempts to lose weight across different racial/ethnic groups. | 1930-739x:Ling, Jiying:ORCID: http://orcid.org/0000-0003-1997-7914:Stommel, Manfred:Choi, Seung Hee:Journal Article:United States:Obesity (Silver Spring). 2018 Feb 1. doi: 10.1002/oby.22106. | null | https://www.ncbi.nlm.nih.gov/pubmed/29388733 | College of Nursing, Michigan State University, East Lansing, Michigan, USA.:Division of Health Informatics and Surveillance, National Center for Health Statistics, Hyattsville, Maryland, USA. | null | null | null | null | null | null | NLM | eng | null | 10.1002/oby.22106 |
27 | Generic | Winkelman, T. N. A. V., N., Kozhimannil, K. B., Davis, M. M., Patrick, S. W., | 2,018 | Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004-2014 | null | Pediatrics | null | 141 | null | 4 | null | null | null | null | 3/25/2018 | Apr | null | null | Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004-2014 | Pediatrics | 0031-4005 | null | null | null | CDC Public Health Grand Rounds | NAS Prevalence and Trends | null | null | null | null | null | 10:26 | 29,572,288 | null | null | null | OBJECTIVES: To describe incidence, health care use, and cost trends for infants with neonatal abstinence syndrome (NAS) who are covered by Medicaid compared with other infants. METHODS: We used 2004-2014 hospital birth data from the National Inpatient Sample, a nationally representative sample of hospital discharges in the United States (N = 13 102 793). Characteristics and trends among births impacted by NAS were examined by using univariate statistics and logistic regression. RESULTS: Medicaid covered 73.7% of NAS-related births in 2004 (95% confidence interval [CI], 68.9%-77.9%) and 82.0% of NAS-related births in 2014 (95% CI, 80.5%-83.5%). Among infants covered by Medicaid, NAS incidence increased more than fivefold during our study period, from 2.8 per 1000 births (95% CI, 2.1-3.6) in 2004 to 14.4 per 1000 births (95% CI, 12.9-15.8) in 2014. Infants with NAS who were covered by Medicaid were significantly more likely to be transferred to another hospital and have a longer length of stay than infants without NAS who were enrolled in Medicaid or infants with NAS who were covered by private insurance. Adjusting for inflation, total hospital costs for NAS births that were covered by Medicaid increased from $65.4 million in 2004 to $462 million in 2014. The proportion of neonatal hospital costs due to NAS increased from 1.6% in 2004 to 6.7% in 2014 among births that were covered by Medicaid. CONCLUSIONS: The number of Medicaid-financed births that are impacted by NAS has risen substantially and totaled $462 million in hospital costs in 2014. Improving affordable health insurance coverage for low-income women before pregnancy would expand access to substance use disorder treatment and could reduce NAS-related morbidity and costs. | 1098-4275:Winkelman, Tyler N A:Villapiano, Nicole:Kozhimannil, Katy B:Davis, Matthew M:Patrick, Stephen W:K23 DA038720/DA/NIDA NIH HHS/United States:Journal Article:United States:Pediatrics. 2018 Apr;141(4). pii: peds.2017-3520. doi: 10.1542/peds.2017-3520. | null | https://www.ncbi.nlm.nih.gov/pubmed/29572288 | Division of General Internal Medicine, Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota; [email protected].:Center for Patient and Provider Experience, Minneapolis Medical Research Foundation, Minneapolis, Minnesota.:Family Health Network, Cortland Regional Medical Center, Cortland, New York.:Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, Minnesota.:Mary Ann & J. Milburn Smith Child Health Research Program, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois.:Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; and.:Departments of Pediatrics and.:Health Policy, School of Medicine, Vanderbilt University, Nashville, Tennessee. | null | null | null | null | null | null | NLM | eng | null | 10.1542/peds.2017-3520 |
28 | Generic | Carroll, M. D. M., M. E., Wolz, M., Srinivas, P. R., | 2,018 | Trends in apolipoprotein B, non-high-density lipoprotein, and low-density lipoprotein for adults 60 years and older by use of lipid-lowering medications: United States, 2005 to 2006 through 2013 to 2014 | null | Circulation | null | 138 | null | 2 | 208-210 | null | null | null | 7/11/2018 | 7-Oct | null | null | Trends in apolipoprotein B, non-high-density lipoprotein, and low-density lipoprotein for adults 60 years and older by use of lipid-lowering medications: United States, 2005 to 2006 through 2013 to 2014 | Circulation | 0009-7322 | null | null | null | CDC Authored Publications | Chronic Diseases and Conditions | null | null | null | null | null | 10:27 | 29,986,963 | null | null | apoliproprotein b:cardiovascular diseases:lipoproteins, HDL:lipoproteins, LDL | null | 1524-4539:Carroll, Margaret D:Mussolino, Michael E:Wolz, Michael:Srinivas, Pothur R:Letter:United States:Circulation. 2018 Jul 10;138(2):208-210. doi: 10.1161/CIRCULATIONAHA.117.031982. | null | https://www.ncbi.nlm.nih.gov/pubmed/29986963 | Division of Health and Nutrition Examination Surveys, National Center for Health Statistics, Hyattsville, MD (M.D.C.). [email protected].:National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (M.E.M., M.W., P.R.S.). | null | null | null | null | null | null | NLM | eng | null | 10.1161/circulationaha.117.031982 |
29 | Generic | Domingo, J. L. N., M., | 2,017 | Per- and polyfluoroalkyl substances (PFASs) in food and human dietary intake: A review of the recent scientific literature | null | J Agric Food Chem | null | 65 | null | 3 | 533-543 | null | null | null | 1/5/2017 | 25-01 | null | null | Per- and polyfluoroalkyl substances (PFASs) in food and human dietary intake: A review of the recent scientific literature | Journal of agricultural and food chemistry | 0021-8561 | null | null | null | Key Scientific Articles in Featured Topic Areas | PFAS - Animal model and toxicology studies | null | null | null | null | null | 10:28 | 28,052,194 | null | null | Alkanesulfonic Acids/*analysis:Caprylates/*analysis:Environmental Exposure/*analysis:Fluorocarbons/*analysis:Food Contamination/*analysis:Humans:*pfoa:*pfos:*dietary intake:*health risks:*per- and polyfluorinated alkyl substances (PFASs) | Because of the important environmental presence and the potential human toxicity of per- and polyfluorinated alkyl substances (PFASs), in recent years the social and scientific interest in these compounds has notably increased. Special attention has been paid to perfluorooctanesulfonate (PFOS) and perfluorooctanoic acid (PFOA), the most extensively investigated PFASs. Although human exposure to PFASs may occur through different pathways, dietary intake seems to be the main route of exposure to these compounds. In 2012, we published a wide revision on the state of the science regarding the concentrations of PFASs in foodstuffs, the human dietary exposure to these compounds, and their health risks. In the present review, we have updated the information recently (2011-2016) published in the scientific literature. As in our previous review, we have also observed considerable differences in the PFASs detected-and their concentrations-in the food items analyzed in samples from a number of regions and countries. However, fish and other seafood seem to be the food group in which more PFASs are detected and where the concentrations of these compounds are higher. On the basis of the recommendations of the EFSA on the maximum dietary intakes of PFOS and PFOA, human health risks would not be of concern for nonoccupationally exposed populations, at least in the very limited countries for which recent data are available. | 1520-5118:Domingo, Jose L:ORCID: http://orcid.org/0000-0001-6647-9470:Nadal, Marti:Journal Article:Review:United States:J Agric Food Chem. 2017 Jan 25;65(3):533-543. doi: 10.1021/acs.jafc.6b04683. Epub 2017 Jan 12. | null | https://www.ncbi.nlm.nih.gov/pubmed/28052194 | Laboratory of Toxicology and Environmental Health, School of Medicine, IISPV, Universitat Rovira i Virgili , Sant Llorenc 21, 43201 Reus, Spain. | null | null | null | null | null | null | NLM | eng | null | 10.1021/acs.jafc.6b04683 |
30 | Generic | Zorrilla, C. D. G. G., I., Garcia Fragoso, L., De La Vega, A. | 2,017 | *Zika virus infection in pregnancy: Maternal, fetal, and neonatal considerations | null | J Infect Dis | null | 216 | null | suppl_10 | S891-s896 | null | null | null | 12/22/2017 | 16-12 | null | null | *Zika virus infection in pregnancy: Maternal, fetal, and neonatal considerations | The Journal of infectious diseases | 0022-1899 | null | null | null | CDC Vital Signs | Zika in Infants | null | null | null | null | null | 10:29 | 29,267,916 | null | null | Zikv:Zika in pregnancy:pregnancy | An infection with the Zika virus (ZIKV) is usually mild, with nonspecific symptoms and most often asymptomatic. However, because of its causal relationship with severe congenital malformations, the ZIKV epidemic became an imperative for mobilization, renewed strategies for vector control, and biomedical research. A congenital Zika syndrome (CZS) has been characterized with 5 distinctive features that focus on brain development abnormalities (including microcephaly and brain calcifications), retinal manifestations, and defects on extremities including congenital contractures and hypertonia. The CZS could be just "the tip of the iceberg", pending the documentation of a spectrum of disease that could manifest later in life, from mild dysfunction to severe disease. It will be a matter of time for neurodevelopmental abnormalities, learning disabilities, and other unknown but yet-to-be-described outcomes to be associated with intrauterine ZIKV infection. In addition, ZIKV infection during pregnancy has been associated with other adverse outcomes. Reports mostly include ZIKV-affected pregnancies, and it will be difficult to clearly establish causality without appropriate control groups. We are summarizing some of the known or reported consequences of such infection during pregnancy. Women of reproductive age and particularly pregnant women are the most vulnerable to the adverse consequences of the ZIKV epidemic. Vector control programs need to be expanded to curtail new infections. Research is needed to develop safe and effective treatments, a preventive or therapeutic vaccine, and specific and sensitive tests and to diagnose and identify correlates of long-term immunity. Vaccines and treatments should be safe to be used in pregnancy. To do nothing would allow thousands of pregnant women to expose their fetuses to an infection that causes birth defects and other problems. Prenatal diagnosis technology development is necessary to be able to predict or diagnose adverse fetal outcomes related to ZIKV. Moreover, these tests should be used in a manner similar to the testing/screening method for neural tube defects and common chromosomal anomalies during prenatal care. | 1537-6613:Zorrilla, Carmen D:Garcia Garcia, Ines:Garcia Fragoso, Lourdes:De La Vega, Alberto:R25 MH083617/MH/NIMH NIH HHS/United States:Journal Article:United States:J Infect Dis. 2017 Dec 16;216(suppl_10):S891-S896. doi: 10.1093/infdis/jix448. | null | https://www.ncbi.nlm.nih.gov/pubmed/29267916 | Department of Obstetrics and Gynecology, University of Puerto Rico School of Medicine, San Juan.:Department of Pediatrics, University of Puerto Rico School of Medicine, San Juan. | null | null | null | null | null | null | NLM | eng | null | 10.1093/infdis/jix448 |
31 | Generic | Beer, K. D. B., D. D., Kadzik, M., Asiedu, K. B., Shieh, W. J., Bower, W., Jackson, B. R., Walke, H., Chiller, T., | 2,018 | A call to action for mycetoma | null | Curr Fungal Infect Rep | null | null | null | null | null | null | null | null | null | null | null | null | A call to action for mycetoma | null | 1936-3761:1936-377X | null | null | null | Top Articles of the Week | Communicable Diseases | null | null | null | null | null | 10:30 | null | null | null | Actinomycetoma:Eumyctoma:Mycetoma:Neglected tropical diseases:article:awareness:controlled study:funding:fungus:human:leprosy:nonhuman:podoconiosis:skin:strategic planning:world health organization | Purpose of Review: Here, we discuss the current needs and priorities for mycetoma control and prevention, highlight lessons learned from leprosy and podoconiosis, and motivate an urgent need to accelerate progress toward reducing the burden of mycetoma in endemic areas. Recent Findings: In 2015, the World Health Assembly (WHA) added mycetoma, a progressively debilitating disease caused by fungi and bacteria, to the World Health Organization (WHO) list of priority neglected tropical diseases (NTDs). Designation of other diseases as NTDs has raised awareness, enabled global partnerships, and advanced the capacity to combat disease through integrated programming. Although key mycetoma etiologic agents have been identified, many questions remain and mycetoma may similarly benefit from NTD designation. Summary: In collaboration with experts at WHO and elsewhere, we formed a global mycetoma working group to connect partners from a variety of sectors and specialties. We envision that this group will evolve into a formalized partnership that can prioritize strategic planning, advocacy, and research needs, identify funding sources, and coordinate activities related to mycetoma and other NTDs affecting the skin. The experiences gained from other NTDs can help to guide the global mycetoma working group's activities to better address the goals set forth in the WHA resolution. | Using Smart Source Parsing:Date of Publication: 2018 | null | https://link.springer.com/article/10.1007%2Fs12281-018-0317-x | (Beer, Jackson, Chiller) Mycotic Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Atlanta, GA 30329, United States (Blaney, Kadzik, Bower, Walke) Bacterial Special Pathogens Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Atlanta, GA 30329, United States (Asiedu) Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland (Shieh) Infectious Diseases Pathology Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Atlanta, GA 30329, United States:K.D. Beer, Mycotic Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Atlanta, GA 30329, United States. E-mail: [email protected] | null | null | null | null | null | Embase | Ovid Technologies | English | null | http://dx.doi.org/10.1007/s12281-018-0317-x |
32 | Generic | Badawy, S. M. P., A. B., Rodeghier, M. J., Liem, R. I., | 2,018 | Exercise capacity and clinical outcomes in adults followed in the Cooperative Study of Sickle Cell Disease (CSSCD) | null | Eur J Haematol | null | 101 | null | 4 | 532-541 | null | null | null | 7/13/2018 | Oct | null | null | Exercise capacity and clinical outcomes in adults followed in the Cooperative Study of Sickle Cell Disease (CSSCD) | European journal of haematology | 0902-4441 | null | null | null | CDC Authored Publications | Chronic Diseases and Conditions | null | null | null | null | null | 10:37 | 29,999,202 | null | null | acute chest syndrome: exercise capacity: fitness: mortality: pain: sickle cell disease | OBJECTIVES: To determine the factors associated with exercise capacity in adults with sickle cell disease (SCD) and its relationship to hospitalizations and mortality. METHODS: A total of 223 participants in the Cooperative Study of Sickle Cell Disease (CSSCD) (64% female, 70% hemoglobin SS/Sbeta(0) thalassemia, mean age 43.3 +/- 7.5 years) underwent maximal exercise testing using a treadmill protocol with a mean duration of 11.6 +/- 5.2 minutes. RESULTS: Female sex (beta = -3.34, 95% CI [-1.80, -4.88], P < 0.001), older age (beta = -0.14, 95% CI [-0.24, -0.04], P = 0.005), higher body mass index (beta = -0.23, 95% CI [-0.37, -0.10]; P = 0.001), and lower hemoglobin (beta = 0.56, 95% CI [0.08, 1.04], P = 0.02) were independently associated with lower fitness, while there was a trend with abnormal pulmonary function testing (beta = -1.42, 95% CI [-2.92, 0.07]; P = 0.06). Lower percent-predicted forced expiratory volume in 1 second (FEV1 ) was independently associated with lower fitness (beta = 0.08, 95% CI [0.03, 0.13], P = 0.001). Genotype and hospitalization rates for pain and acute chest syndrome (ACS) prior to testing were not associated with exercise capacity. Baseline exercise capacity predicted neither future pain or ACS nor survival in our cohort. Adults with SCD tolerated maximal exercise testing. CONCLUSIONS: Prospective studies are needed to further evaluate the impact of regular exercise and improved fitness on clinical outcomes and mortality in SCD. | 1600-0609: Badawy, Sherif M: ORCID: http://orcid.org/0000-0002-4739-265X: Payne, Amanda B: Rodeghier, Mark J: Liem, Robert I: K12HS023011/Agency for Healthcare Research and Quality: Journal Article: England: Eur J Haematol. 2018 Oct;101(4):532-541. doi: 10.1111/ejh.13140. Epub 2018 Aug 31. | null | https://www.ncbi.nlm.nih.gov/pubmed/29999202 | Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.: Department of Pediatrics, Northwestern University Feinberg School Medicine, Chicago, Illinois.: Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia.: Rodeghier Consultants, Chicago, Illinois. | null | null | null | null | null | null | NLM | eng | null | 10.1111/ejh.13140 |
33 | Generic | Kahkoska, A. R. I., S., Divers, J., Mayer-Davis, E. J., Dolan, L., Shah, A. S., Afkarian, M., Pettitt, D. J., Lawrence, J. M., Marcovina, S., Saydah, S. H., Dabelea, D., Maahs, D. M., Mottl, A. K., | 2,018 | The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes | null | J Diabetes Complications | null | null | null | null | null | null | null | null | 10/15/2018 | 10-Apr | null | null | The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes | Journal of diabetes and its complications | 1056-8727 | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 10:41 | 30,316,542 | null | null | Albuminuria: Epidemiology: Nephropathy: Pediatric type 1 diabetes: Pediatric type 2 diabetes | AIMS: To determine among adolescents and young adults with youth-onset type 1 diabetes and type 2 diabetes the rates and risk factors for albuminuria regression and progression. METHODS: Data from SEARCH, a longitudinal observational study of youth-onset type 1 diabetes (N=1316) and type 2 diabetes (N=143) were analyzed. Urine albumin:creatinine ratio (UACR) was measured from random urine specimens at baseline and follow-up visits (mean 7years later). Albuminuria regression was defined as halving of baseline UACR when baseline UACR was >/=30mug/mg; progression was defined as doubling of baseline UACR when follow-up UACR was >/=30mug/mg, respectively. Multivariable regression assessed risk factors associated with low-risk albuminuria category (combined persistently-low albuminuria and regression) versus moderate-risk albuminuria category (combined persistently-high albuminuria and progression). RESULTS: Albuminuria progression was more common in type 2 diabetes versus type 1 diabetes (15.4% versus 6.0%, p<0.001). Moderate-risk albuminuria was associated with increasing HbA1c (adjusted OR (aOR)=1.3, 95% CI 1.1-1.6) and lack of private health insurance (aOR=2.7, 95%CI 1.1-6.5) in type 1 diabetes; and African American race (OR=4.6, 95% CI 1.2-14.2), lower estimated insulin sensitivity score (aOR=2.1, 95% CI 1.4-3.3), baseline UACR (aOR=3.2, 95% CI 1.7-5.8), and follow-up estimated glomerular filtration rate (eGFR) (10-unit increase aOR=1.3, 95% CI 1.0, 1.5) in type 2 diabetes. CONCLUSIONS: In the first decade of diabetes duration, kidney complications in type 2 diabetes are significantly more aggressive than in type 1 diabetes and may be associated with less modifiable risk factors including race, insulin sensitivity, and eGFR. Early interventions may help reduce long-term kidney complications. | 1873-460x: Kahkoska, Anna R: Isom, Scott: Divers, Jasmin: Mayer-Davis, Elizabeth J: Dolan, Lawrence: Shah, Amy S: Afkarian, Maryam: Pettitt, David J: Lawrence, Jean M: Marcovina, Santica: Saydah, Sharon H: Dabelea, Dana: Maahs, David M: Mottl, Amy K: SEARCH for Diabetes in Youth Study Group: Journal Article: United States: J Diabetes Complications. 2018 Oct 4. pii: S1056-8727(18)30730-X. doi: 10.1016/j.jdiacomp.2018.09.018. | null | https://www.ncbi.nlm.nih.gov/pubmed/30316542 | Department of Nutrition, University of North Carolina at Chapel Hill, 135 Dauer Drive, Chapel Hill, NC 27599, USA. Electronic address: [email protected].: Dept. of Biostatistical Sciences, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.: Department of Medicine, University of North Carolina at Chapel Hill, 321 S. Columbia St, Chapel Hill, NC 27516, USA.: Division of Endocrinology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA.: Division of Nephrology, Department of Medicine, University of California, Davis, 4610 X St, Sacramento, CA 95817, USA.: 2219 Bath St., Santa Barbara, CA 93105, USA.: Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles Ave, Pasadena, CA 91101, USA.: Northwest Lipid Metabolism and Diabetes Research Laboratories, Dept. of Medicine, University of Washington, 401 Queen Anne Avenue North, UW Mailbox 359119, Seattle, WA 98109, USA.: Division of Diabetes Translation, US Centers for Disease Control and Prevention, National Center for Health Statistics, 3311 Toledo Rd, Hyattsville, MD 20782, USA.: Department of Epidemiology, School of Public Health, University of Colorado Denver, 13001 E 17th Pl, Aurora, CO 80045, USA.: Division of Pediatric Endocrinology, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA 94305, USA.: University of North Carolina Kidney Center, UNC School of Medicine, 101 Manning Dr, Chapel Hill, NC 27514, USA. | null | null | null | null | null | null | NLM | eng | null | 10.1016/j.jdiacomp.2018.09.018 |
34 | Generic | Nahid, P. M., S. R.;Migliori, G. B.;Sotgiu, G.;Bothamley, G. H.;Brozek, J. L.;Cattamanchi, A.;Cegielski, J. P.;Chen, L.;Daley, C. L.;Dalton, T. L.;Duarte, R.;Fregonese, F.;Horsburgh, C. R., Jr.;Ahmad Khan, F.;Kheir, F.;Lan, Z.;Lardizabal, A.;Lauzardo, M.;Mangan, J. M.;Marks, S. M.;McKenna, L.;Menzies, D.;Mitnick, C. D.;Nilsen, D. M.;Parvez, F.;Peloquin, C. A.;Raftery, A.;Schaaf, H. S.;Shah, N. S.;Starke, J. R.;Wilson, J. W.;Wortham, J. M.;Chorba, T.;Seaworth, B. | 2,019 | Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA Clinical Practice Guideline | null | Am J Respir Crit Care Med | null | 200 | null | 10 | e93-e142 | null | null | null | 11/16/2019 | 15-11 | null | null | Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA Clinical Practice Guideline | null | 1073-449x | null | null | null | Top Articles of the Week | Communicable Diseases | null | null | null | null | null | 12:01 | 31,729,908 | null | null | Mdr-tb:drug treatment:duration of treatment:treatment monitoring:tuberculosis | Background: The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB). The document includes recommendations on the treatment of multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-susceptible TB.Methods: Published systematic reviews, meta-analyses, and a new individual patient data meta-analysis from 12,030 patients, in 50 studies, across 25 countries with confirmed pulmonary rifampin-resistant TB were used for this guideline. Meta-analytic approaches included propensity score matching to reduce confounding. Each recommendation was discussed by an expert committee, screened for conflicts of interest, according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.Results: Twenty-one Population, Intervention, Comparator, and Outcomes questions were addressed, generating 25 GRADE-based recommendations. Certainty in the evidence was judged to be very low, because the data came from observational studies with significant loss to follow-up and imbalance in background regimens between comparator groups. Good practices in the management of MDR-TB are described. On the basis of the evidence review, a clinical strategy tool for building a treatment regimen for MDR-TB is also provided.Conclusions: New recommendations are made for the choice and number of drugs in a regimen, the duration of intensive and continuation phases, and the role of injectable drugs for MDR-TB. On the basis of these recommendations, an effective all-oral regimen for MDR-TB can be assembled. Recommendations are also provided on the role of surgery in treatment of MDR-TB and for treatment of contacts exposed to MDR-TB and treatment of isoniazid-resistant TB. | 1535-4970:Nahid, Payam:ORCID: http://orcid.org/0000-0003-2811-1311:Mase, Sundari R:ORCID: http://orcid.org/0000-0001-5363-0637:Migliori, Giovanni Battista:ORCID: http://orcid.org/0000-0002-2597-574X:Sotgiu, Giovanni:ORCID: http://orcid.org/0000-0002-1600-4474:Bothamley, Graham H:ORCID: http://orcid.org/0000-0002-7092-8547:Brozek, Jan L:ORCID: http://orcid.org/0000-0002-3122-0773:Cattamanchi, Adithya:ORCID: http://orcid.org/0000-0002-6553-2601:Cegielski, J Peter:Chen, Lisa:ORCID: http://orcid.org/0000-0001-6804-0111:Daley, Charles L:ORCID: http://orcid.org/0000-0003-3324-926X:Dalton, Tracy L:Duarte, Raquel:Fregonese, Federica:Horsburgh, C Robert Jr:ORCID: http://orcid.org/0000-0001-6838-7895:Ahmad Khan, Faiz:ORCID: http://orcid.org/0000-0003-0473-8734:Kheir, Fayez:ORCID: http://orcid.org/0000-0002-4192-5080:Lan, Zhiyi:ORCID: http://orcid.org/0000-0001-5519-2474:Lardizabal, Alfred:ORCID: http://orcid.org/0000-0003-3273-1097:Lauzardo, Michael:ORCID: http://orcid.org/0000-0002-7096-4185:Mangan, Joan M:ORCID: http://orcid.org/0000-0001-6770-086X:Marks, Suzanne M:ORCID: http://orcid.org/0000-0003-3024-1940:McKenna, Lindsay:ORCID: http://orcid.org/0000-0002-4703-0835:Menzies, Dick:Mitnick, Carole D:ORCID: http://orcid.org/0000-0002-3455-658X:Nilsen, Diana M:Parvez, Farah:ORCID: http://orcid.org/0000-0003-1211-5043:Peloquin, Charles A:ORCID: http://orcid.org/0000-0001-9002-7052:Raftery, Ann:Schaaf, H Simon:ORCID: http://orcid.org/0000-0001-5755-4133:Shah, Neha S:Starke, Jeffrey R:Wilson, John W:Wortham, Jonathan M:Chorba, Terence:ORCID: http://orcid.org/0000-0001-7722-0958:Seaworth, Barbara:ORCID: http://orcid.org/0000-0003-2922-4940:Journal Article:United States:Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST. | null | https://www.ncbi.nlm.nih.gov/pubmed/31729908 | null | null | null | null | null | null | null | NLM | eng | null | 10.1164/rccm.201909-1874ST |
35 | Generic | Alanazi, K. H. A., G. R.;Midgley, C. M.;Alkhamis, A.;Alsaqer, T.;Almoaddi, A.;Algwizani, A.;Ghazal, S. S.;Assiri, A. M.;Jokhdar, H.;Gerber, S. I.;Alabdely, H.;Watson, J. T. | 2,020 | Diabetes mellitus, hypertension, and death among 32 patients with MERS-CoV infection, Saudi Arabia | null | Emerg Infect Dis | null | 26 | null | 1 | 166-168 | null | null | null | 12/20/2019 | Jan | null | null | Diabetes mellitus, hypertension, and death among 32 patients with MERS-CoV infection, Saudi Arabia | null | 1080-6040 | null | null | null | Top Articles of the Week | Communicable Diseases | null | null | null | null | null | 12:03 | 31,855,530 | null | null | MERS-CoV:Middle East respiratory syndrome coronavirus:Saudi Arabia:death:diabetes mellitus:hypertension:infection:underlying conditions:vector-borne infections:viruses:zoonoses | Diabetes mellitus and hypertension are recognized risk factors for severe clinical outcomes, including death, associated with Middle East respiratory syndrome coronavirus infection. Among 32 virus-infected patients in Saudi Arabia, severity of illness and frequency of death corresponded closely with presence of multiple and more severe underlying conditions. | 1080-6059:Alanazi, Khalid H:Abedi, Glen R:Midgley, Claire M:Alkhamis, Abdulrahim:Alsaqer, Taghreed:Almoaddi, Abdullah:Algwizani, Abdullah:Ghazal, Sameeh S:Assiri, Abdullah M:Jokhdar, Hani:Gerber, Susan I:Alabdely, Hail:Watson, John T:Journal Article:United States:Emerg Infect Dis. 2020 Jan;26(1):166-168. doi: 10.3201/eid2601.190952. | null | https://www.ncbi.nlm.nih.gov/pubmed/31855530 | null | null | null | null | null | null | null | NLM | eng | null | 10.3201/eid2601.190952 |
36 | Generic | P. P. Vart, N. R.;McCulloch, C. E.;Saran, R.;Gillespie, B. W.;Saydah, S.;Crews, D. C. | 2,020 | National trends in the prevalence of chronic kidney disease among racial/ethnic and socioeconomic status groups, 1988-2016 | null | JAMA Netw Open | null | 3 | null | 7 | e207932 | null | null | null | 7/17/2020 | 7-Jan | null | null | National trends in the prevalence of chronic kidney disease among racial/ethnic and socioeconomic status groups, 1988-2016 | null | 2574-3805 | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 12:25 | 32,672,828 | null | null | null | Importance: The overall prevalence of chronic kidney disease (CKD) has stabilized in the United States in recent years. However, it is unclear whether all major sociodemographic groups experienced this trend. Objective: To examine trends in CKD prevalence across major sociodemographic groups as defined by race/ethnicity and socioeconomic status. Design, Setting, and Participants: This repeated cross-sectional study used data from the National Health and Nutrition Examination Surveys for 1988 to 1994 and every 2 years from 1999 to 2016 on individuals 20 years or older with information on race/ethnicity, socioeconomic status, and serum creatinine levels. Statistical analysis was conducted from May 1, 2017, to April 6, 2020. Exposures: Race/ethnicity and socioeconomic status. Main Outcomes and Measures: Prevalence of CKD was defined as an estimated glomerular filtration rate of 15 to 59 mL/min/1.73 m2. Results: A total of 54554 participants (mean [SE] age, 46.2 [0.2] years; 51.7% female) were examined. The age-, sex- and race/ethnicity-adjusted overall prevalence of stage 3 and 4 CKD increased from 3.9% in 1988-1994 to 5.2% in 2003-2004 (difference, 1.3%; 95% CI, 0.9%-1.7%; P < .001 for change) and remained relatively stable thereafter at 5.1% in 2015-2016 (difference, -0.1%; 95% CI, -0.7% to 0.4%; P = .61 for change). The trend in adjusted CKD prevalence differed significantly by race/ethnicity (P = .009 for interaction). In non-Hispanic white and non-Hispanic black persons, CKD prevalence increased between 1988-1994 and 2003-2004 and remained stable thereafter. Among Mexican American persons, CKD prevalence was lower than in other racial/ethnic groups and remained stable between 1988-1994 and 2003-2004 but nearly doubled (difference, 2.1%; 95% CI, 0.9%-3.3%; P = .001 for change) between 2003-2004 and 2015-2016 to rates similar to those in other racial/ethnic groups. There were higher rates of CKD prevalence among groups with lower educational level and income (eg, 5.8% vs 4.3% and 4.3% vs 3.1% in low vs high education and income, respectively, in 1988-1994), but trends in CKD prevalence mirrored those for the overall population. The higher CKD prevalence among individuals with lower educational level and income remained largely consistent throughout the entire period. Results were similar in most subgroups when including albuminuria to define CKD. Conclusions and Relevance: The prevalence of CKD in the United States has stabilized overall in recent years but has increased among Mexican American persons. More important, gaps in CKD prevalence across racial/ethnic groups and levels of socioeconomic status largely persisted over 28 years. There is a need to identify and address causes of increasing CKD prevalence among Mexican American persons and a need to renew efforts to effectively mitigate persistent disparities in CKD prevalence. | 2574-3805:Vart, Priya:Powe, Neil R:McCulloch, Charles E:Saran, Rajiv:Gillespie, Brenda W:Saydah, Sharon:Crews, Deidra C:Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team:Journal Article:United States:JAMA Netw Open. 2020 Jul 1;3(7):e207932. doi: 10.1001/jamanetworkopen.2020.7932. | null | https://www.ncbi.nlm.nih.gov/pubmed/32672828 | Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.:Zuckerberg San Francisco General Hospital and Trauma Center, Department of Medicine, University of California, San Francisco.:Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco.:Kidney Epidemiology and Cost Center, University of Michigan, Ann Arbor.:Division of Nephrology, Department of Medicine, University of Michigan, Ann Arbor.:Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia.:Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.:Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland.:Johns Hopkins Center for Health Equity, Johns Hopkins Medical Institutions, Baltimore, Maryland. | null | null | null | null | null | null | null | eng | null | 10.1001/jamanetworkopen.2020.7932 |
37 | Generic | Beale, L. H., S., Abellan, J. J., Lefevre, S., Jarup, L., | 2,010 | Evaluation of spatial relationships between health and the environment: the rapid inquiry facility | null | Environ Health Perspect | null | 118 | null | 9 | 1306-1312 | null | null | null | 5/12/2010 | Sep | null | null | Evaluation of spatial relationships between health and the environment: the rapid inquiry facility | Environmental health perspectives | 0091-6765 | null | null | null | Key Scientific Articles in Featured Topic Areas | Environmental Health | null | null | null | null | null | null | 20,457,552 | null | null | Environmental Exposure/adverse effects: Environmental Health/*methods: Epidemiology: Geographic Information Systems: Great Britain: Public Health/*methods: Risk Factors: United States | BACKGROUND: The initiation of environmental public health tracking systems in the United States and the United Kingdom provided an opportunity to advance techniques and tools available for spatial epidemiological analysis integrating both health and environmental data. OBJECTIVE: The Rapid Inquiry Facility (RIF) allows users to calculate adjusted and unadjusted standardized rates and risks. The RIF is embedded in ArcGIS so that further geographical information system (GIS) spatial functionality can be exploited or results can be exported to statistical packages for further tailored analyses where required. The RIF also links directly to several statistical packages and displays the results in the GIS. METHODS: The value of the RIF is illustrated here with two case studies: risk of leukemia in areas surrounding oil refineries in the State of Utah (USA) and an analysis of the geographical variation of risk of esophageal cancer in relation to zinc cadmium sulfide exposure in Norwich (United Kingdom). RESULTS: The risk analysis study in Utah did not suggest any evidence of increased relative risk of leukemia, multiple myeloma, or Hodgkin's lymphoma in the populations around the five oil-refining facilities but did reveal an excess risk of non-Hodgkin's lymphoma that might warrant further investigation. The disease-mapping study in Norwich did not reveal any areas with higher relative risks of esophageal cancer common to both males and females, suggesting that a common geographically determined exposure was unlikely to be influencing cancer risk in the area. CONCLUSION: The RIF offers a tool that allows epidemiologists to quickly carry out ecological environmental epidemiological analysis such as risk assessment or disease mapping. | 1552-9924: Beale, Linda: Hodgson, Susan: Abellan, Juan Jose: Lefevre, Sam: Jarup, Lars: 1-U38-EH000182/EH/NCEH CDC HHS/United States: G0801056/Medical Research Council/United Kingdom: N01-PC-35141/PC/NCI NIH HHS/United States: Journal Article: Research Support, N.I.H., Extramural: Research Support, Non-U.S. Gov't: Research Support, U.S. Gov't, P.H.S.: United States: Environ Health Perspect. 2010 Sep;118(9):1306-12. doi: 10.1289/ehp.0901849. Epub 2010 May 10. | null | http://www.ncbi.nlm.nih.gov/pubmed/20457552/?otool=cdciclib | Small Area Health Statistics Unit, MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, Imperial College London, UK. [email protected] | null | null | null | null | null | null | NLM | eng | null | 10.1289/ehp.0901849 |
38 | Generic | Engle-Stone, R. N., M., Ndjebayi, A. O., Allen, L. H., Shahab-Ferdows, S., Hampel, D., Killilea, D. W., Gimou, M. M., Houghton, L. A., Friedman, A., Tarini, A., Stamm, R. A., Brown, K. H., | 2,017 | Iron, zinc, folate, and vitamin B-12 status increased among women and children in Yaounde and Douala, Cameroon, 1 year after introducing fortified wheat flour | null | J Nutr | null | 147 | null | 7 | 1426-1436 | null | null | null | 6/9/2017 | Jul | null | null | Iron, zinc, folate, and vitamin B-12 status increased among women and children in Yaounde and Douala, Cameroon, 1 year after introducing fortified wheat flour | The Journal of nutrition | 0022-3166 | null | null | null | CDC Public Health Grand Rounds | Maternal and Child Health - Global Prevention of Neural Tube Defects | null | null | null | null | null | 9:41 | 28,592,513 | null | null | Adolescent: Adult: Cameroon: Diet: Female: Flour/*analysis: Folic Acid/*blood: *Food, Fortified: Humans: Infant: Iron/*blood: Male: Middle Aged: Nutritional Status: Surveys and Questionnaires: Vitamin B 12/*blood: Young Adult: Zinc/*blood: breast milk: effectiveness: folate: fortification: iron: vitamin B-12: zinc: interest. RE-S, MN, AON, AT, and KHB received research funding from Sight and: Life for the current study. RE-S received conference travel support from Sight: and Life for an unrelated project. | Background: Few data are available on the effectiveness of large-scale food fortification programs.Objective: We assessed the impact of mandatory wheat flour fortification on micronutrient status in Yaounde and Douala, Cameroon.Methods: We conducted representative surveys 2 y before and 1 y after the introduction of fortified wheat flour. In each survey, 10 households were selected within each of the same 30 clusters (n = approximately 300 households). Indicators of inflammation, malaria, anemia, and micronutrient status [plasma ferritin, soluble transferrin receptor (sTfR), zinc, folate, and vitamin B-12] were assessed among women aged 15-49 y and children 12-59 mo of age.Results: Wheat flour was consumed in the past 7 d by >/=90% of participants. Postfortification, mean total iron and zinc concentrations of flour samples were 46.2 and 73.6 mg/kg (target added amounts were 60 and 95 mg/kg, respectively). Maternal anemia prevalence was significantly lower postfortification (46.7% compared with 39.1%; adjusted P = 0.01), but mean hemoglobin concentrations and child anemia prevalence did not differ. For both women and children postfortification, mean plasma concentrations were greater for ferritin and lower for sTfR after adjustments for potential confounders. Mean plasma zinc concentrations were greater postfortification and the prevalence of low plasma zinc concentration in women after fortification (21%) was lower than before fortification (39%, P < 0.001); likewise in children, the prevalence postfortification (28%) was lower than prefortification (47%, P < 0.001). Mean plasma total folate concentrations were approximately 250% greater postfortification among women (47 compared with 15 nmol/L) and children (56 compared with 20 nmol/L), and the prevalence of low plasma folate values was <1% after fortification in both population subgroups. In a nonrepresentative subset of plasma samples, folic acid was detected in 77% of women (73% of those fasting) and 93% of children. Mean plasma and breast-milk vitamin B-12 concentrations were >50% greater postfortification.Conclusion: Although the pre-post survey design limits causal inference, iron, zinc, folate, and vitamin B-12 status increased among women and children in urban Cameroon after mandatory wheat flour fortification. | 1541-6100: Engle-Stone, Reina: ORCID: http://orcid.org/0000-0003-2446-6166: Nankap, Martin: Ndjebayi, Alex O: Allen, Lindsay H: Shahab-Ferdows, Setareh: Hampel, Daniela: ORCID: http://orcid.org/0000-0003-0288-7680: Killilea, David W: ORCID: http://orcid.org/0000-0002-8929-6527: Gimou, Marie-Madeleine: Houghton, Lisa A: ORCID: http://orcid.org/0000-0002-2276-6205: Friedman, Avital: Tarini, Ann: Stamm, Rosemary A: Brown, Kenneth H: Journal Article: United States: J Nutr. 2017 Jul;147(7):1426-1436. doi: 10.3945/jn.116.245076. Epub 2017 Jun 7. | null | http://www.ncbi.nlm.nih.gov/pubmed/28592513 | Department of Nutrition, University of California, Davis, Davis, CA; [email protected].: Helen Keller International, New York, NY.: Department of Nutrition, University of California, Davis, Davis, CA.: USDA, Agricultural Research Service Western Human Nutrition Research Center, Davis, CA.: Nutrition and Metabolism Center, Children's Hospital Oakland Research Institute, Oakland, CA.: Pasteur Center, Yaounde, Cameroon.: University of Otago, Dunedin, New Zealand; and.: Bill & Melinda Gates Foundation, Seattle, WA. | null | null | null | null | null | null | NLM | eng | null | 10.3945/jn.116.245076 |
39 | Generic | Welch, S. R. S., F. E. M., Flint, M., Chatterjee, P., Nichol, S. T., Bergeron, E., Spiropoulou, C. F., | 2,017 | Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus | null | Antiviral Res | null | null | null | null | null | null | null | null | 10/13/2017 | 10-Sep | null | null | Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus | Antiviral research | 0166-3542 | null | null | null | CDC Authored Publications | Zoonotic and Vectorborne Diseases | null | null | null | null | null | 9:42 | 29,024,765 | null | null | null | Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne orthonairovirus, causes a severe hemorrhagic disease in humans (Crimean-Congo hemorrhagic fever, CCHF). Currently, no vaccines are approved to prevent CCHF; treatment is limited to supportive care and the use of ribavirin, the therapeutic benefits of which remain unclear. CCHF is part of WHO's priority list of infectious diseases warranting further research and development. To aid in the identification of new antiviral compounds, we generated a recombinant CCHFV expressing a reporter protein, allowing us to quantify virus inhibition by measuring the reduction in fluorescence in infected cells treated with candidate compounds. The screening assay was readily adaptable to high-throughput screening (HTS) of compounds using Huh7 cells, with a signal-to-noise ratio of 50:1, and Z'-factors > 0.6 in both 96- and 384-well formats. A screen of candidate nucleoside analog compounds identified 2'-deoxy-2'-fluorocytidine (EC50 = 61 +/- 18 nM) as having 200 x the potency of ribavirin (EC50 = 12.5 +/- 2.6 muM), as well as 17 x the potency of T-705 (favipiravir), another compound with reported anti-CCHFV activity (EC50 = 1.03 +/- 0.16 muM). Furthermore, we also determined that 2'-deoxy-2'-fluorocytidine acts synergistically with T-705 to inhibit CCHFV replication without causing cytotoxicity. The incorporation of this reporter virus into the high-throughput screening assay described here will allow more rapid identification of effective therapeutic options to combat this emerging human pathogen. | 1872-9096: Welch, Stephen R: Scholte, Florine E M: Flint, Mike: Chatterjee, Payel: Nichol, Stuart T: Bergeron, Eric: Spiropoulou, Christina F: Journal Article: Netherlands: Antiviral Res. 2017 Oct 9. pii: S0166-3542(17)30545-4. doi: 10.1016/j.antiviral.2017.10.008. | null | https://www.ncbi.nlm.nih.gov/pubmed/29024765 | Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, MS G-14, Atlanta, GA, 30329, USA.: Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, MS G-14, Atlanta, GA, 30329, USA. Electronic address: [email protected]. | null | null | null | null | null | null | NLM | eng | null | 10.1016/j.antiviral.2017.10.008 |
40 | Generic | Grund, J. M. B., T. S., Jackson, I., Curran, K., Bock, N., Toledo, C., Taliano, J., Zhou, S., Del Campo, J. M., Yang, L., Kivumbi, A., Li, P., Pals, S., Davis, S. M., | 2,017 | Association between male circumcision and women's biomedical health outcomes: a systematic review | null | Lancet Glob Health | null | 5 | null | 11 | e1113-e1122 | null | null | null | 10/14/2017 | Nov | null | null | Association between male circumcision and women's biomedical health outcomes: a systematic review | The Lancet. Global health | 2214-109x | null | null | null | Top Articles of the Week | Communicable Diseases | null | null | null | null | null | 9:43 | 29,025,633 | null | null | null | BACKGROUND: Male circumcision reduces men's risk of acquiring HIV and some sexually transmitted infections from heterosexual exposure, and is essential for HIV prevention in sub-Saharan Africa. Studies have also investigated associations between male circumcision and risk of acquisition of HIV and sexually transmitted infections in women. We aimed to review all evidence on associations between male circumcision and women's health outcomes to benefit women's health programmes. METHODS: In this systematic review we searched for peer-reviewed and grey literature publications reporting associations between male circumcision and women's health outcomes up to April 11, 2016. All biomedical (not psychological or social) outcomes in all study types were included. Searches were not restricted by year of publication, or to sub-Saharan Africa. Publications without primary data and not in English were excluded. We extracted data and assessed evidence on each outcome as high, medium, or low consistency on the basis of agreement between publications; outcomes found in fewer than three publications were indeterminate consistency. FINDINGS: 60 publications were included in our assessment. High-consistency evidence was found for five outcomes, with male circumcision protecting against cervical cancer, cervical dysplasia, herpes simplex virus type 2, chlamydia, and syphilis. Medium-consistency evidence was found for male circumcision protecting against human papillomavirus and low-risk human papillomavirus. Although the evidence shows a protective association with HIV, it was categorised as low consistency, because one trial showed an increased risk to female partners of HIV-infected men resuming sex early after male circumcision. Seven outcomes including HIV had low-consistency evidence and six were indeterminate. INTERPRETATION: Scale-up of male circumcision in sub-Saharan Africa has public health implications for several outcomes in women. Evidence that female partners are at decreased risk of several diseases is highly consistent. Synergies between male circumcision and women's health programmes should be explored. FUNDING: US Centers for Disease Control and Prevention and Jhpiego. | 2214-109x:Grund, Jonathan M:Bryant, Tyler S:Jackson, Inimfon:Curran, Kelly:Bock, Naomi:Toledo, Carlos:Taliano, Joanna:Zhou, Sheng:Del Campo, Jorge Martin:Yang, Ling:Kivumbi, Apollo:Li, Peizi:Pals, Sherri:Davis, Stephanie M:Journal Article:England:Lancet Glob Health. 2017 Nov;5(11):e1113-e1122. doi: 10.1016/S2214-109X(17)30369-8. | null | http://www.ncbi.nlm.nih.gov/pubmed/29025633 | US Centers for Disease Control and Prevention, Division of Global HIV and TB, Atlanta, GA, USA.:Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.:Jhpiego, Baltimore, MD, USA.:US Centers for Disease Control and Prevention, Library Science Branch, Division of Public Health Information Dissemination, Center for Surveillance, Epidemiology, and Laboratory Services, Atlanta, GA, USA.:US Centers for Disease Control and Prevention, Division of Global HIV and TB, Atlanta, GA, USA. Electronic address: [email protected]. | null | null | null | null | null | null | NLM | eng | null | 10.1016/s2214-109x(17)30369-8 |
41 | Generic | Fitter, D. L. D., D. B., Guillaume, F. D., Schaad, A. W., Moffett, D. B., Poncelet, J. L., Lowrance, D., Gelting, R., | 2,017 | Applying a new framework for public health systems recovery following emergencies and disasters: The example of Haiti following a major earthquake and cholera outbreak | null | Am J Trop Med Hyg | null | null | 97 | null | 4_Suppl | 44662 | null | null | 10/25/2017 | Oct | null | null | Applying a new framework for public health systems recovery following emergencies and disasters: The example of Haiti following a major earthquake and cholera outbreak | The American journal of tropical medicine and hygiene | 0002-9637 | null | null | null | Top Articles of the Week | Disaster Control and Emergency Services | null | null | null | null | null | 9:44 | 29,064,359 | null | null | null | Emergencies can often directly impact health systems of an affected region or country, especially in resource-constrained areas. Health system recovery following an emergency is a complex and dynamic process. Health system recovery efforts have often been structured around the World Health Organization's health systems building blocks as demonstrated by the Post-Disaster Needs Assessment. Although this structure is valuable and well known, it can overlook the intricacies of public health systems. We retrospectively examine public health systems recovery, a subset of the larger health system, following the 2010 Haiti earthquake and cholera outbreak, through the lens of the 10 essential public health services. This framework illustrates the comprehensive nature of and helps categorize the activities necessary for a well-functioning public health system and can complement other assessments. Outlining the features of a public health system for recovery in structured manner can also help lay the foundation for sustainable long-term development leading to a more robust and resilient health system. | 1476-1645:Fitter, David L:Delson, Daphnee Benoit:Guillaume, Florence D:Schaad, Angela Wood:Moffett, Daphne B:Poncelet, Jean-Luc:Lowrance, David:Gelting, Richard:Journal Article:United States:Am J Trop Med Hyg. 2017 Oct;97(4_Suppl):4-11. doi: 10.4269/ajtmh.16-0862. | null | http://www.ncbi.nlm.nih.gov/pubmed/29064359/?otool=cdciclib | Centers for Disease Control and Prevention, Port-au-Prince, Haiti.:Ministry of Public Health and Population, Port-au-Prince, Haiti.:Management Sciences for Health (MSH), Port-au-Prince, Haiti.:Centers for Disease Control and Prevention, Atlanta, Georgia.:Centers for Disease Control and Prevention, Almaty, Kazakhstan.:Pan American Health Organization, Port-au-Prince, Haiti.:Centers for Disease Control and Prevention, Dar es Salaam, Tanzania. | null | null | null | null | null | PubMed | NLM | eng | null | 10.4269/ajtmh.16-0862 |
42 | Generic | Razzaghi, H. S., M., Thompson, T. D., Henley, S. J., Viens, L., Wilson, R., | 2,017 | Five-year relative survival for human papillomavirus-associated cancer sites | null | Cancer | null | null | null | null | null | null | null | null | 11/7/2017 | 11-Jun | null | null | Five-year relative survival for human papillomavirus-associated cancer sites | Cancer | 0008-543x | null | null | null | Top Articles of the Week | Chronic Diseases and Conditions | null | null | null | null | null | 9:46 | 29,105,738 | null | null | HPV-associated cancer:human papillomavirus (HPV) cancer:relative survival | BACKGROUND: Human papillomavirus (HPV) vaccines can potentially prevent greater than 90% of cervical and anal cancers as well as a substantial proportion of vulvar, vaginal, penile, and oropharyngeal cancers caused by certain HPV types. Because more than 38,000 HPV-associated cancers are diagnosed annually in the United States, current studies are needed to understand how relative survival varies for each of these cancers by certain demographic characteristics, such as race and age. METHODS: The authors examined high-quality data from 27 population-based cancer registries covering approximately 59% of the US population. The analyses were limited to invasive cancers that were diagnosed during 2001 through 2011 and followed through 2011 and met specified histologic criteria for HPV-associated cancers. Five-year relative survival was calculated from diagnosis until death for these cancers by age, race, and sex. RESULTS: The 5-year age-standardized relative survival rate was 64.2% for cervical carcinomas, 52.8% for vaginal squamous cell carcinomas (SCCs), 66% for vulvar SCCs, 47.4% for penile SCCs, 65.9% for anal SCCs, 56.2% for rectal SCCs, and 51.2% for oropharyngeal SCCs. Five-year relative survival was consistently higher among white patients compared with black patients for all HPV-associated cancers across all age groups; the greatest differences by race were observed for oropharyngeal SCCs among those aged <60 years and for penile SCCs among those ages 40 to 49 years compared with other age groups. CONCLUSIONS: There are large disparities in relative survival among patients with HPV-associated cancers by sex, race, and age. HPV vaccination and improved access to screening (of cancers for which screening tests are available) and treatment, especially among groups that experience higher incidence and lower survival, may reduce disparities in survival from HPV-associated cancers. Cancer 2017. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. | 1097-0142:Razzaghi, Hilda:ORCID: http://orcid.org/0000-0002-8053-9748:Saraiya, Mona:Thompson, Trevor D:Henley, S Jane:Viens, Laura:Wilson, Reda:ORCID: http://orcid.org/0000-0002-3252-9625:Journal Article:United States:Cancer. 2017 Nov 6. doi: 10.1002/cncr.30947. | null | http://www.ncbi.nlm.nih.gov/pubmed/29105738 | National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.:Epidemic Intelligence Service Program, Centers for Disease Control and Prevention, Atlanta, Georgia. | null | null | null | null | null | null | NLM | eng | null | 10.1002/cncr.30947 |
43 | Generic | Centers for Disease Control and Prevention | 2,017 | Monitoring selected national HIV prevention and care objectives by using HIV surveillance data - United States and 6 dependent areas, 2015 | null | HIV Surveillance Supplemental Report | null | null | 22 | null | 2 | null | null | null | null | null | null | null | Monitoring selected national HIV prevention and care objectives by using HIV surveillance data - United States and 6 dependent areas, 2015 | null | null | null | null | null | CDC Vital Signs | Communicable Diseases | null | null | null | null | null | 9:47 | null | null | null | null | null | null | null | https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-22-2.pdf | null | null | null | null | null | null | null | null | null | null | null |
44 | Generic | Deokar, A. J. D., A., DeFiore-Hyrmer, J., Laidler, M., Millet, L., Morman, S., Myers, L., | 2,018 | State injury programs' response to the opioid epidemic: The role of CDC's Core Violence and Injury Prevention Program | null | J Public Health Manag Pract | null | null | null | null | S23-s31 | null | null | null | 12/1/2017 | Jan/Feb | null | null | State injury programs' response to the opioid epidemic: The role of CDC's Core Violence and Injury Prevention Program | Journal of public health management and practice : JPHMP | 1078-4659 | null | null | null | Top Ten Articles of the Week | Injury and Violence | null | null | null | null | null | 9:49 | 29,189,501 | null | null | null | The Centers for Disease Control and Prevention's (CDC's) Core Violence and Injury Prevention Program (Core) supports capacity of state violence and injury prevention programs to implement evidence-based interventions. Several Core-funded states prioritized prescription drug overdose (PDO) and leveraged their systems to identify and respond to the epidemic before specific PDO prevention funding was available through CDC. This article describes activities employed by Core-funded states early in the epidemic. Four case examples illustrate states' approaches within the context of their systems and partners. While Core funding is not sufficient to support a comprehensive PDO prevention program, having Core in place at the beginning of the emerging epidemic had critical implications for identifying the problem and developing systems that were later expanded as additional resources became available. Important components included staffing support to bolster programmatic and epidemiological capacity; diverse and collaborative partnerships; and use of surveillance and evidence-informed best practices to prioritize decision-making. | 1550-5022:Deokar, Angela J:Dellapenna, Alan:DeFiore-Hyrmer, Jolene:Laidler, Matt:Millet, Lisa:Morman, Sara:Myers, Lindsey:Journal Article:United States:J Public Health Manag Pract. 2018 Jan/Feb;24 Suppl 1 Supplement, Injury and Violence Prevention:S23-S31. doi: 10.1097/PHH.0000000000000704. | null | https://www.ncbi.nlm.nih.gov/pubmed/29189501 | Division of Analysis, Research and Practice Integration, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia (Ms Deokar); Injury and Violence Prevention Branch, North Carolina Department of Health and Human Services, Raleigh, North Carolina (Mr Dellapenna), Ohio Violence and Injury Prevention Program, Ohio Department of Health, Columbus, Ohio (Mss Defiore-Hyrmer and Morman); Injury and Violence Prevention Section, Oregon Health Authority, Salem, Oregon (Mr Laidler and Ms Millet); and Violence and Injury Prevention-Mental Health Promotion Branch, Colorado Department of Health and Environment, Denver, Colorado (Ms Myers). | null | null | null | null | null | Top Ten Articles of the Week | NLM | eng | null | 10.1097/phh.0000000000000704 |
45 | Generic | Geter, A. S., M. Y., Hubbard McCree, D., | 2,018 | Social and structural determinants of HIV treatment and care among black women living with HIV infection: a systematic review: 2005-2016 | null | AIDS Care | null | null | null | null | 44569 | null | null | null | 1/30/2018 | 28-01 | null | null | Social and structural determinants of HIV treatment and care among black women living with HIV infection: a systematic review: 2005-2016 | AIDS care | 0954-0121 | null | null | null | Top Articles of the Week | Communicable Diseases | null | null | null | null | null | 10:05 | 29,376,409 | null | null | African Americans:HIV care continuum:HIV-positive:disparities:women | Black/African American (black) women comprised 59% of women living with HIV at the end of 2014 and 61% of HIV diagnoses among women in 2015. Black women living with HIV infection (BWLH) have poorer health outcomes compared with women of other races/ethnicities; social and structural determinants are often cited as barriers and facilitators of care. The objective of this qualitative review was to identify social and structural barriers and facilitators of HIV treatment and care among BWLH. The systematic review was conducted in six-stages using databases such as PubMed, PsycINFO, and Google Scholar: 1) searched for studies that enrolled BWLH published between January 2005 and December 2016, 2) excluded unpublished reports and commentaries, 3) limited the search to our primary keywords, 4) limited our search to studies that included participants living with HIV infection that were >60% black and 100% female, 5) extracted and summarized the data, and 6) conducted a contextual review to identify common themes. Of 534 studies retrieved, 16 were included in the final review. Studies focused on: ART medication adherence (n = 5), engagement/retention in care (n = 4), HIV care and treatment services (n = 3), viral suppression (n = 1), and addressing multiple HIV care outcomes (n = 3). Main barrier themes included lack of family and/or social support, poor quality HIV services, and HIV-related stigma, particularly from healthcare providers; facilitator themes included resilience, positive relationships between case management and support services, high racial consciousness, and addressing mental health. Interventions that decrease these noted barriers and strengthen facilitators may help improve care outcomes for BWLH. Also, more HIV stigma-reduction training for healthcare providers may be warranted. | 1360-0451:Geter, Angelica:Sutton, Madeline Y:Hubbard McCree, Donna:Journal Article:England:AIDS Care. 2018 Jan 28:1-8. doi: 10.1080/09540121.2018.1426827. | null | https://www.ncbi.nlm.nih.gov/pubmed/29376409 | a Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention , Atlanta , GA , USA. | null | null | null | null | null | null | NLM | eng | null | 10.1080/09540121.2018.1426827 |
46 | Generic | Ko, J. Y. P., S. W., Tong, V. T., Patel, R., Lind, J. N., Barfield, W. D., | 2,016 | Incidence of neonatal abstinence syndrome - 28 states, 1999-2013 | null | MMWR Morb Mortal Wkly Rep | null | 65 | null | 31 | 799-802 | null | null | null | 8/12/2016 | 8-Dec | null | null | Incidence of neonatal abstinence syndrome - 28 states, 1999-2013 | MMWR. Morbidity and mortality weekly report | 0149-2195 | null | null | null | CDC Public Health Grand Rounds | NAS Prevalence and Trends | null | null | null | null | null | 10:26 | 27,513,154 | null | null | Databases, Factual:Humans:Incidence:Infant, Newborn:Neonatal Abstinence Syndrome/*epidemiology:United States/epidemiology | Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome that occurs primarily among opioid-exposed infants shortly after birth, often manifested by central nervous system irritability, autonomic overreactivity, and gastrointestinal tract dysfunction (1). During 2000-2012, the incidence of NAS in the United States significantly increased (2,3). Several recent publications have provided national estimates of NAS (2,3); however, data describing incidence at the state level are limited. CDC examined state trends in NAS incidence using all-payer, hospital inpatient delivery discharges compiled in the State Inpatient Databases of the Healthcare Cost and Utilization Project (HCUP) during 1999-2013. Among 28 states with publicly available data in HCUP during 1999-2013, the overall NAS incidence increased 300%, from 1.5 per 1,000 hospital births in 1999, to 6.0 per 1,000 hospital births in 2013. During the study period, significant increases in NAS incidence occurred in 25 of 27 states with at least 3 years of data, with annual incidence rate changes ranging from 0.05 (Hawaii) to 3.6 (Vermont) per 1,000 births. In 2013, NAS incidence ranged from 0.7 cases per 1,000 hospital births (Hawaii) to 33.4 cases per 1,000 hospital births (West Virginia). The findings underscore the importance of state-based public health programs to prevent unnecessary opioid use and to treat substance use disorders during pregnancy, as well as decrease the incidence of NAS. | 1545-861x:Ko, Jean Y:Patrick, Stephen W:Tong, Van T:Patel, Roshni:Lind, Jennifer N:Barfield, Wanda D:K23 DA038720/DA/NIDA NIH HHS/United States:Journal Article:United States:MMWR Morb Mortal Wkly Rep. 2016 Aug 12;65(31):799-802. doi: 10.15585/mmwr.mm6531a2. | null | https://www.ncbi.nlm.nih.gov/pubmed/27513154 | null | null | null | null | null | null | null | NLM | eng | null | 10.15585/mmwr.mm6531a2 |
47 | Generic | Jackson, S. L. Z., Z., Wiltz, J. L., Loustalot, F., Ritchey, M. D., Goodman, A. B., Yang, Q., | 2,018 | Hypertension among youths - United States, 2001-2016 | null | MMWR Morb Mortal Wkly Rep | null | 67 | null | 27 | 758-762 | null | null | null | 7/13/2018 | 13-07 | null | null | Hypertension among youths - United States, 2001-2016 | MMWR. Morbidity and mortality weekly report | 0149-2195 | null | null | null | CDC Authored Publications | Chronic Diseases and Conditions | null | null | null | null | null | 10:27 | 30,001,558 | null | null | null | Hypertension is an important modifiable risk factor for cardiovascular morbidity and mortality, and hypertension in adolescents and young adults is associated with long-term negative health effects (1,2).* In 2017, the American Academy of Pediatrics (AAP) released a new Clinical Practice Guideline (3), which updated 2004 pediatric hypertension guidance(dagger) with new thresholds and percentile references calculated from a healthy-weight population. To examine trends in youth hypertension and the impact of the new guideline on classification of hypertension status, CDC analyzed data from 12,004 participants aged 12-19 years in the 2001-2016 National Health and Nutrition Examination Survey (NHANES). During this time, prevalence of hypertension declined, using both the new (from 7.7% to 4.2%, p<0.001) and former (from 3.2% to 1.5%, p<0.001) guidelines, and declines were observed across all weight status categories. However, because of the new percentile tables and lower threshold for hypertension (4), application of the new guideline compared with the former guideline resulted in a weighted net estimated increase of 795,000 U.S. youths being reclassified as having hypertension using 2013-2016 data. Youths who were older, male, and those with obesity accounted for a disproportionate share of persons reclassified as having hypertension. Clinicians and public health professionals might expect to see a higher prevalence of hypertension with application of the new guideline and can use these data to inform actions to address hypertension among youths. Strategies to improve cardiovascular health include adoption of healthy eating patterns and increased physical activity (3). | 1545-861x:Jackson, Sandra L:Zhang, Zefeng:Wiltz, Jennifer L:Loustalot, Fleetwood:Ritchey, Matthew D:Goodman, Alyson B:Yang, Quanhe:Journal Article:United States:MMWR Morb Mortal Wkly Rep. 2018 Jul 13;67(27):758-762. doi: 10.15585/mmwr.mm6727a2. | null | https://www.ncbi.nlm.nih.gov/pubmed/30001558 | null | null | null | null | null | null | null | NLM | eng | null | 10.15585/mmwr.mm6727a2 |
End of preview.
Science Clips
Description
CDC Science Clips is an online bibliographic digest featuring scientific articles and publications that are shared with the public health community each week, to enhance awareness of emerging scientific knowledge.
Dataset Details
- Publisher: Centers for Disease Control and Prevention
- Last Modified: 2024-07-09
- Contact: Jarvis Sims ([email protected])
Source
Original data can be found at: https://data.cdc.gov/d/biid-68vb
Usage
You can load this dataset using:
from datasets import load_dataset
dataset = load_dataset('HHS-Official/science-clips')
License
This dataset is licensed under http://opendefinition.org/licenses/odc-odbl/
- Downloads last month
- 31